



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Clinical characteristics, prognosis, and risk prediction model for adverse outcomes in patients suspected of coronary artery diseases and no significant stenosis on angiography

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-092614
Article Type:	Original research
Date Submitted by the Author:	19-Aug-2024
Complete List of Authors:	Zhu, Lei; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Xue, Zheng-Kai; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Wu, Xue; University of California San Francisco, Institute for Global Health Sciences Zhang, JingKun; University of California San Francisco Hu, Su-Tao; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Zhang, Yu-Kun; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Gu, Tian-Shu; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Liu, Tong; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Rha, Seung-Woon; Korea University Guro Hospital, Cardiovascular Center Chen, Kang-Yin; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology
Keywords:	Angina Pectoris, Coronary heart disease < CARDIOLOGY, Prognosis

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Clinical characteristics, prognosis, and risk prediction model for adverse outcomes in patients suspected of coronary artery diseases and no significant stenosis on angiography

Authors: Lei Zhu¹, Zheng-Kai Xue¹, Xue Wu², Jing-Kun Zhang³, Su-Tao Hu¹, Yu-Kun Zhang¹, Tian-Shu Gu¹, Tong Liu¹, Seung-Woon Rha⁴, Kang-Yin Chen^{1*}

Affiliations: ¹ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China.

² Institute for Global Health Sciences, University of California, San Francisco, CA, USA

³ Cardiovascular Research Institute, University of California San Francisco, CA, USA

⁴ Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.

***Corresponding author:** Kang-Yin Chen, MD, PhD, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China (chenkangyin@vip.126.com)

Word count: 2939

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background and objectives

Although patients with suspected coronary artery disease and no significant stenosis on angiography are thought to have a better prognosis, some still experience adverse outcomes. This study aims to develop a predictive model for these adverse outcomes.

Methods

We retrospectively enrolled patients diagnosed with angina with nonobstructive coronary arteries (ANOCA) between January 2019 and June 2023, collecting relevant clinical data. We employed LASSO regression to select adverse prognostic risk factors, which were then integrated into a Cox proportional hazards regression model. Subsequently, we created a nomogram. Model performance was assessed for discrimination and calibration using the areas under the curve (AUC) and calibration plots, along with internal validation. The nomogram was utilized to categorize patients into high- and low-risk groups, and we compared their survival differences using the log-rank test.

Results

4,452 patients were included in the training cohort, and 1,482 in the testing cohort. The nomogram incorporated eight variables: age, hemoglobin, serum urea, serum sodium, ALT/AST ratio, NT-proBNP, left atrial diameter, and LVEF. It showed good predictive performance for 1-year, 2-year, and 3-year event-free survival probabilities in both the training cohorts (AUC 0.82, 0.90, and 0.89) and testing cohorts (AUC 0.75, 0.77, and 0.78). Calibration plots revealed close alignment between

predicted and actual event-free survival probabilities in both cohorts. Significant survival differences were observed among risk groups (log-rank $p < 0.0001$).

Conclusions

This study has successfully established a predictive model for adverse outcomes in ANOCA patients using clinically accessible variables, which could serve as a valuable tool to risk-stratify patients and customize their management and treatment strategies.

Key word

angina, coronary artery disease, MINOCA, prognosis, nomogram.

Backgrounds

Chest pain is a common symptom among patients seeking medical services, often raising concerns about potentially life-threatening conditions such as coronary artery disease (CAD) [1,2]. Timely and accurate diagnostic assessments, including electrocardiography, coronary computed tomography angiography, and coronary angiography, are frequently recommended for individuals presenting with chest pain to rule out severe conditions such as myocardial infarction (MI) [3,4]. However, in the cohort of patients undergoing diagnostic workup, approximately half exhibit nonobstructive coronary arteries (stenosis less than 50%)[5,6], a condition known as angina with nonobstructive coronary arteries (ANOCA) [7].

1
2
3
4 55
5
6
7 56 ANOCA patients often seek medical care due to symptoms and undergo repetitive invasive
8
9
10 57 examinations, leading to significant healthcare resource utilization and imposing individual burdens
11
12 58 and additional risks [8–10]. In a randomized controlled trial involving over 10,000 patients suspected
13
14
15 59 of CAD with intermediate pretest likelihood, only approximately 12% of them yielded a positive result
16
17
18 60 in the final coronary artery functional tests [11]. Patients with a low pretest probability exhibit an
19
20
21 61 exceedingly low positivity rate in diagnostic workup and experience fewer adverse outcomes [12].
22
23 62 Therefore, clinical guidelines recommend delaying diagnostic testing for patients at low risk for
24
25
26 63 CAD[13,14]. However, patients without obstructive coronary arteries confirmed by coronary
27
28
29 64 angiography (CAG) or coronary computed tomography angiography (CCTA) have been observed to
30
31
32 65 experience more adverse outcomes compared to the general population[15–17]. Identifying high-
33
34 66 risk patients remains a challenge.
35
36
37 67
38
39 68 There is limited research on predicting adverse outcomes in ANOCA patients confirmed through CAG
40
41
42 69 or CCTA. Some studies have validated the utility of specific pretest indicators, such as age, sex, and
43
44
45 70 traditional cardiovascular disease risk factors(e.g., hypertension), to identify low-risk ANOCA patients
46
47
48 71 [18]. However, several investigations have shown that specific blood biomarkers, including high-
49
50
51 72 sensitivity troponin and lower HDL-C levels, operate as independent predictive factors for poor
52
53
54 73 prognosis in ANOCA patients, adding prognostic value[19]. To date, comprehensive studies that
55
56
57 74 screen noninvasive indicators and develop a prognostic model are lacking, and most previous studies
58
59
60 75 are reliant on data derived from the Women's Ischemia Syndrome Evaluation (WISE) study[19–21],

which exclusively includes female participants. One study also used WISE data to validate the effectiveness of some risk scores originally designed for other populations, such as the ASCVD score, in predicting adverse outcomes in ANOCA patients, but the results showed suboptimal performance [22]. Therefore, it is necessary to develop a predictive model based on non-invasive indicators to forecast adverse outcomes in ANOCA patients of both sexes. This study aims to bridge this gap to optimize clinical decision-making and patient management.

Method

Study Population

This is a retrospective cohort study that consecutively enrolled patients who presented with suspected symptoms of CAD and underwent coronary angiography at the Department of Cardiology or Emergency Department of the Second Hospital of Tianjin Medical University between January 2019 and June 2023. The Second Hospital of Tianjin Medical University is a cardiac center serving the northern Chinese city of Tianjin and its surrounding regions. This study adheres to the principles outlined in the TRIPOD statement [23].

Patients meeting the following criteria were excluded from the study: (1) patients with acute coronary syndrome or obstructive coronary arteries (defined as a luminal stenosis of $\geq 50\%$ in a major epicardial coronary artery); (2) patients with a prior diagnosis of CAD, history of percutaneous coronary

1
2
3
4 96 intervention (PCI), or coronary artery bypass grafting (CABG); (3) individuals with severe liver or
5
6
7 97 kidney dysfunction, malignancies, or other conditions significantly affecting life expectancy; (4) those
8
9
10 98 with substantial missing baseline data; and (5) patients lost to follow-up. This study received approval
11
12 99 from the Ethics Committee of the Second Hospital of Tianjin Medical University, and the requirement
13
14
15 100 for written informed consent from patients was waived.

16
17
18 101
19
20
21
22 102 **Clinical Data Collection**

23
24
25 103 Patient data were retrospectively obtained from electronic medical records, including demographic
26
27
28 104 information, medical history, vital sign data, laboratory parameters, echocardiographic data, coronary
29
30
31 105 angiography findings and other relevant details.

32
33
34 106
35
36
37
38 107 **Follow-Up and Endpoints**

39
40
41 108 Trained follow-up team members conducted regular patient follow-up after discharge at 30 days, 3
42
43
44 109 months, 6 months, and annually thereafter. Follow-up was performed using the hospital information
45
46
47 110 system, telephone, or email. The follow-up data for this study were collected up to August 1, 2023.

48
49
50 111
51
52 112 The primary endpoint was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or
53
54
55 113 coronary-artery bypass grafting (CABG) during follow-up. The secondary endpoint was major adverse
56
57
58 114 cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat

PCI, and CABG during follow-up.

Statistical Analysis

For the small amount of missing data in smoking and alcohol consumption history, multiple imputation was performed using the MICE package (Multiple Imputation by Chained Equations package). To establish a reliable model, the entire study cohort was randomly stratified into two subsets, a training set and a validation set, with a ratio of 0.75 to 0.25, respectively. The training set was used to generate the predictive model, while the validation set was utilized for model internal validation.

Categorical variables were described as frequencies and percentages, with group differences assessed using the chi-square test or Fisher's exact test as applicable. Continuous variables were expressed as either the mean \pm standard deviation (SD) or median [interquartile range, IQR], and group comparisons were conducted using the t test or Kruskal–Wallis test as appropriate. The variables selected through LASSO regression were incorporated into the Cox proportional hazards regression model, and a nomogram was generated based on the Cox regression analysis model. The discriminative ability of the predictive model was evaluated using AUC. The model's calibration was assessed through the calibration curve. Additionally, decision curve analysis was employed to evaluate the clinical utility of the nomogram.

The total score for each patient was calculated based on the nomogram, and the study population was

1
2
3
4 135 stratified into high-risk and low-risk groups according to the score corresponding to the 3-year 95%
5
6
7 136 event-free survival probability. Event-free survival for the high- and low-risk groups in the training
8
9
10 137 and validation sets was estimated by Kaplan–Meier method and compared with the log-rank test. All
11
12 138 statistical analyses were performed with R software version 4.3.1 (R Foundation for Statistical
13
14
15 139 Computing). All statistical tests were two- tailed, with a significance level set at P<0.05.

16
17
18 140
19
20 141
21
22
23
24 142 **Result**

25
26
27
28 143 **Study Population and Patient Characteristics**

29
30
31
32 144 Out of a consecutive cohort of 17,816 patients who underwent coronary angiography for suspected
33
34
35 145 coronary artery disease, 9,883 individuals with significant coronary artery stenosis and 1,816 patients
36
37 146 with a documented history of coronary heart disease were excluded. An additional 131 individuals
38
39
40 147 were excluded due to missing baseline or follow-up data, and 52 patients with severe conditions such
41
42
43 148 as malignant tumors were also excluded. of the final analysis included 5,934 patients with negative
44
45
46 149 coronary angiography results (**Figure 1**).

47
48 150
49
50
51 151 The mean age of the overall cohort was 43.6 ± 10.8 years, with 58.3% being female, and the median
52
53
54 152 follow-up time was 631 [270, 972] days. Detailed baseline data are provided in **Supplementary Table**
55
56 153 **1**. During the follow-up period, 145 (2.44%) patients had primary endpoint events, 82 (1.38%) had
57
58
59 154 MACE, 106 (1.79%) had all-cause death, 33 (0.56%) had MI, and 11 (0.19%) had a stroke. The
60

Kaplan-Meier method was employed to estimate the survival without various adverse events for the total study population (**Supplementary Figure 1**).

Nomogram built based on LASSO-COX regression

The entire cohort was randomly divided into a training cohort consisting of 4,452 patients and a validation cohort comprising 1,482 patients. There were no statistically significant differences in the collected variables between these two groups (**Supplementary Table 1**). LASSO regression was employed to select variables with the strongest correlation to the primary endpoint. As the regularization parameter (λ) increased, certain coefficients were reduced to zero, effectively eliminating those variables from the model (**Figure 2A**). We used a tenfold cross-validation approach to identify the optimal model. Due to the relatively limited number of cases undergoing primary endpoint events in the validation cohort (145), we employed the one standard error (1-se) rule, resulting in eight selected variables (**Figure 2B**). These variables were incorporated into a Cox proportional hazards regression model, with results presented in **Table 2**. A nomogram was developed based on the Cox regression model, with the regression coefficients of these factors amalgamated into a scoring system, ranging from 0 to 100(**Figure 3**). For example, an 81-year-old male patient with a hemoglobin level of 92 g/L, serum urea of 14.1 mmol/L, serum sodium of 145.6 mmol/L, an ALT/AST ratio of 1.68, NT-proBNP at 272 ng/L, left atrial diameter of 38.83 millimeters, and an LVEF of 62% received a total score of 115. The 1-year, 2-year and 3-year event-free survival rates were 99.5%, 96.2% and 89.0%, respectively.

1
2
3
4 175
5
6
7 176
8
9
10 177
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 178
29
30 179
31
32
33 180
34
35
36
37 181
38
39
40
41 182
42
43
44 183
45
46 184
47
48
49 185
50
51
52 186
53
54 187
55
56
57 188
58
59
60 189

Table 2. Prediction of event-free survival probability using the Cox proportional hazards regression model based on LASSO regression.

Variable	coefficients	z score	HR	95%CI	p value
Age	0.043	4.167	1.044	0.023, 0.063	<0.001
Hemoglobin	-0.015	-2.871	0.985	-0.026, -0.005	0.004
Urea	0.074	3.947	1.077	0.037, 0.111	<0.001
Serum sodium	-0.074	-5.694	0.929	-0.1, -0.049	<0.001
ALT/AST ratio	0.444	2.439	1.559	0.087, 0.8	0.015
NT-proBNP	0	2.094	1	0, 0	0.036
Left atrial diameter	0.076	5.959	1.079	0.051, 0.8	<0.001
LVEF	-0.022	-2.289	0.979	-0.04, -0.003	0.022

HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; AST, aspartate transaminase; LVEF, left ventricular ejection fraction.

Discrimination and calibration of the nomogram

The discriminative ability of the model was assessed by plotting receiver operating characteristic curves. In the training set, the AUC for 1-, 2-, and 3-year predictions was 0.82, 0.90, and 0.89, respectively. In the validation set, the corresponding AUC for 1-, 2-, and 3-year predictions were 0.75, 0.77, and 0.78, respectively (**figure 4**).

Figure 5 illustrates calibration plots for the models predicting 1-, 2-, and 3-year survival in both the training and validation datasets. In well-calibrated models, the points closely align with the ideal 45-degree line, indicating that predicted survival closely matches observed survival and demonstrating

good model calibration.

Decision Curve

Decision curve analysis was employed to evaluate the potential improvement in clinical outcomes through nomogram-assisted decision-making for patients. As illustrated in **Figure 6**, the results reveal that across a broad spectrum of threshold probabilities in both the training and testing cohorts, utilizing the nomogram for predicting the 2-year or 3-year event-free survival probability offers a more significant net benefit when compared to strategies of 'treat all' or 'treat none.' These findings underscore the clinical utility of the nomogram.

Risk stratification

Considering that the study population consists of low-risk patients with non-obstructive coronary artery stenosis, the threshold for further risk stratification was set at a higher event-free survival probability, specifically a score of 104 points corresponding to the 95% 3-year event-free survival probability as determined by the nomogram. Individuals scoring below this threshold were categorized as low-risk, while those scoring equal to or above it were classified as high-risk. Kaplan-Meier curves depicting event-free survival were created for the two risk groups in the training and validation sets (**Figure 7**). Furthermore, MACE-event free survival of these groups is shown in **Supplementary Figure 2**. These results consistently demonstrated the model's efficacy in patient risk stratification.

1
2
3
4 209
5
6
7 210
8
9
10
11 211
12
13
14 212
15
16
17 213
18
19
20 214
21
22
23 215
24
25 216
26
27
28 217
29
30
31 218
32
33 219
34
35
36 220
37
38
39 221
40
41
42 222
43
44 223
45
46
47 224
48
49
50 225
51
52 226
53
54
55 227
56
57
58 228
59
60

Discussion

This study focused on patients initially suspected of having CAD but who were found to have nonobstructive coronary arteries following coronary angiography. A wide range of variables, including demographic information, vital signs, laboratory parameters, and echocardiographic measurements, were meticulously examined. Ultimately, 8 key variables, namely age, hemoglobin levels, serum urea, serum sodium levels, ALT/AST ratio, NT-proBNP levels, left atrial diameter, and LVEF, were identified. The study successfully developed a nomogram to predict the probability of event-free survival for these patients, demonstrating excellent discriminatory and calibration abilities in both the training and validation sets. The utilization of this predictive model in clinical practice empowers healthcare providers to conduct more precise risk stratification, particularly for individuals initially classified as low-risk, thereby improving diagnostic, management, and treatment strategies and ultimately enhancing patient outcomes.

In clinical practice, a substantial number of patients with potential cardiac issues, such as chest pain, actively seek medical attention in both outpatient and emergency department settings. In the United Kingdom, for instance, approximately 1-2% of adults consult primary care facilities when experiencing chest pain for the first time [15]. Similarly, millions of individuals in the United States undergo stress tests in outpatient clinics each year for undiagnosed heart conditions [24]. However, research has

consistently shown that following diagnostic assessments like coronary angiography, approximately 50% of patients do not exhibit obstructive coronary artery stenosis [5,16,25,26]. Traditionally, such patients were often considered to have a favorable prognosis and no significant cardiac conditions, potentially resulting in the omission of further diagnostic measures and therapeutic interventions [27–29]. However, recent research has indicated that these patients face a significantly elevated risk of adverse outcomes compared to the general population. The WISE study revealed that at over a 10-year follow-up, patients without obstructive coronary stenosis on coronary angiography had rates of cardiovascular death and MI of 6.7% and 12.8%, respectively, underscoring the heightened risk among female ANOCA patients [21,30,31]. Other studies have also demonstrated that ANOCA patients, regardless of their gender, face an increased risk of experiencing CAD-related outcomes compared to the general population[16,26,32].

Our findings from this study indicate that ANOCA patients tend to be younger, with an average age of 43.6 years, and a higher proportion of them are female (58.3%) [7]. During a median follow-up period of 2 years, the rates of all-cause death, MI, and stroke were 1.79%, 0.56%, and 0.19%, respectively. These findings align with a previous study reporting 1-year MI rates ranging from 0.11% to 0.59% and 1-year mortality rates ranging from 1.38% to 2.3% [26]. Our research further supports the characterization of ANOCA patients and provides additional evidence of their elevated risk for adverse outcomes across diverse populations.

While clinical guidelines suggest risk stratification of chest pain patients and deferring testing for those

1
2
3
4 250 with a low likelihood of CAD, this strategy may inadvertently exclude high-risk ANOCA patients who
5
6
7 251 require further assessment and appropriate therapeutic interventions [13,14]. As highlighted in a recent
8
9
10 252 review, a significant proportion of ANOCA patients (ranging from 75% to 90%) exhibit various
11
12 253 underlying causes, such as coronary microvascular dysfunction (CMD), microvascular spasm,
13
14
15 254 endothelial dysfunction, epicardial coronary spasm, and/or myocardial bridging [7,33], emphasizing
16
17
18 255 the critical importance of identifying high-risk ANOCA patients to optimize their further management.
19
20 256
21
22
23 257 Current research on factors related to adverse outcomes in the ANOCA population is limited. One
24
25
26 258 study attempted to develop a risk tool for chest pain patients with normal coronary arteries to predict
27
28
29 259 favorable outcomes. This tool comprised 10 variables, including age, gender, and the presence of
30
31 260 conditions like hypertension, diabetes, or dyslipidemia. However, it is important to note that this study
32
33
34 261 solely relied solely on pretest clinical data and accessed coronary arteries through coronary CTA [18].
35
36
37 262 In contrast, our predictive model incorporated pre-test indicators, including demographic variables and
38
39
40 263 medical history, with age being one of the key factors. Age is a variable included in many traditional
41
42 264 CAD prediction models because it is easily obtainable and reflects the aging of the entire
43
44
45 265 cardiovascular system, including increased arterial stiffness and decreased vascular endothelial
46
47
48 266 function [22,34].
49
50 267
51
52
53 268 Previous studies have also indicated that several blood biomarkers are associated with unfavorable
54
55
56 269 outcomes in ANOCA patients, including lower levels of HDL-C, elevated levels of soluble urokinase-
57
58
59 270 type plasminogen activator receptor, and high-sensitivity troponin [19,20]. However, none of these
60

studies conducted comprehensive screening of clinical variables or developed a predictive model. After a thorough screening of blood biomarkers, our predictive model incorporated hemoglobin, serum urea, serum sodium and NT-proBNP, which are rarely reported to be associated with adverse outcomes in ANOCA patients. Anemia, for example, is a common pathological condition involved in the occurrence and development of CAD and heart failure through various mechanisms [35]. It significantly increases the risk of developing CAD and heart failure and is associated with adverse outcomes in these patients [36,37]. Serum urea reflects renal function, which is a crucial factor influencing the cardiovascular system [38]. Previous research has shown that an elevated serum urea levels increase the risk of CAD and serve as a predictive factors for adverse outcomes in CAD and heart failure patients [39,40]. The role of serum sodium in cardiovascular disease is still not fully understood, but several studies have indicated that even mild reductions in serum sodium, even within the normal range, are associated with higher all-cause mortality and cardiovascular mortality in elderly individuals or the general population [41–44]. The underlying mechanisms behind this association require further research. NT-proBNP is a widely recognized marker for heart failure and exhibits strong predictive capabilities for the prognosis of heart failure patients [45]. Previous studies have also demonstrated its ability to predict cardiovascular events and mortality even in community-dwelling or elderly populations without heart failure [46–49].

Our predictive model also considered echocardiographic parameters. Echocardiography is a noninvasive, easily performed, and cost-effective imaging technique that provides comprehensive insights into cardiac structure and function. In our model, left atrial diameter and LVEF were included.

1
2
3
4 292 Left atrial enlargement is closely associated with conditions like atrial fibrillation and heart failure,
5
6
7 293 and factors such as hypertension and mitral valve diseases can also lead to left atrial enlargement. It is
8
9
10 294 commonly regarded as a biomarker for adverse cardiovascular outcomes [50–53]. The LVEF serves
11
12 295 as one of the diagnostic and classificatory criteria for heart failure, with the latter often signifying the
13
14
15 296 advanced stage of diverse cardiac ailments and indicates an unfavorable prognosis [54,55].
16
17
18 297

19
20 298 **Strengths and limitations**
21
22

23 299 This study has several limitations. First, it is a retrospective study conducted at a single medical center,
24
25
26 300 which may introduce some potential biases. Second, the study population consisted entirely of
27
28
29 301 individuals from northern China, so caution should be exercised when generalizing the findings of this
30
31 302 study to other populations. Third, due to the limitations of retrospective research, we were unable to
32
33
34 303 further subdivide nonobstructive coronary stenosis into "normal coronary" (without significant
35
36
37 304 coronary atherosclerosis) and "nonobstructive CAD" (stenosis <50%), although these two groups may
38
39 305 have similar subsequent management. Finally, the predictive model lacks validation in an external
40
41
42 306 population, but internal validation was performed, and it demonstrated good discrimination and
43
44
45 307 calibration.
46
47
48 308

49
50 309
51
52
53
54 310 **Conclusion**
55
56

57
58 311 In summary, we conducted a comprehensive evaluation of clinically accessible variables and
59
60

successfully developed a predictive model for assessing adverse outcomes in patients with suspected CAD who do not exhibit obstructive coronary artery stenosis. This nomogram equips clinicians with a valuable tool for risk stratification in ANOCA patients, allowing for optimized management and treatment strategies aimed at improving patient outcomes.

List of abbreviations

ANOCA, angina with nonobstructive coronary arteries

ACU, areas under the curve

ALT, alanine transaminase

AST, aspartate transaminase

LVEF, left ventricular ejection fraction

CAD, coronary artery disease

MI, myocardial infarction

CAG, coronary angiography

CCTA, coronary computed tomography angiography

HDL-C, high-density lipoprotein cholesterol

PCI, percutaneous coronary intervention

CABG, coronary-artery bypass grafting

MACE, major adverse cardiovascular events

1
2
3
4 332
5
6
7 333
8
9
10 334
11
12 335
13
14
15
16 336
17
18
19
20 337
21
22
23 338
24
25 339
26
27
28 340
29
30
31
32 341
33
34
35
36 342
37
38 343
39
40
41 344
42
43
44 345
45
46
47
48 346
49
50
51 347
52
53
54 348
55
56
57 349
58
59
60 350

Sources of Funding

This study was supported by the Key Project of Tianjin Natural Science Foundation (Grant Number: 21JCZDJC01080), Academic Backbone of “Clinical Talent Training and Climbing Plan” of Tianjin Medical University and Sponsored by Tianjin Health Research Project.

Availability of data and materials

The original data supporting the findings of this study can be obtained from the corresponding author upon request.

Author contributions

ZL and CKY conceived and designed the protocol; ZL, XZK, HST, ZYK, and GTS collected the data; ZL analyzed the data; ZL wrote the manuscript; CKY, RHW, LT, ZJK, XZK, HST, ZYK, GTS and WX critically revised the manuscript. All authors contributed to the article and approved the submitted version.

Disclosures

The authors do not have any associations that are pertinent to the subject matter of this paper to disclose.

References

- 1 Hoorweg BB, Willemsen RT, Cleef LE, *et al.* Frequency of chest pain in primary care, diagnostic tests performed and final diagnoses. *Heart Br Card Soc.* 2017;103:1727–32. doi: 10.1136/heartjnl-2016-310905
- 2 Tsao CW, Aday AW, Almarzooq ZI, *et al.* Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation.* 2022;145:e153–639. doi: 10.1161/CIR.0000000000001052
- 3 Virani SS, Newby LK, Arnold SV, *et al.* 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation.* 2023;148:e9–119. doi: 10.1161/CIR.0000000000001168
- 4 Fihn SD, Gardin JM, Abrams J, *et al.* 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart

1
2
3 376 Association Task Force on Practice Guidelines, and the American College of Physicians, American
4 377 Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for
5 378 Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation*.
6 379 2012;126:3097–137. doi: 10.1161/CIR.0b013e3182776f83
7
8
9
10380 5 Patel MR, Peterson ED, Dai D, *et al*. Low diagnostic yield of elective coronary angiography. *N*
11381 *Engl J Med*. 2010;362:886–95. doi: 10.1056/NEJMoa0907272
12
13382 6 Rahman H, Corcoran D, Aetesam-Ur-Rahman M, *et al*. Diagnosis of patients with angina and non-
14383 obstructive coronary disease in the catheter laboratory. *Heart Br Card Soc*. 2019;105:1536–42.
15384 doi: 10.1136/heartjnl-2019-315042
16384
17
18385 7 Samuels BA, Shah SM, Widmer RJ, *et al*. Comprehensive Management of ANOCA, Part 1-
19386 Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review. *J Am Coll Cardiol*.
20386 2023;82:1245–63. doi: 10.1016/j.jacc.2023.06.043
21387
22
23388 8 Shaw LJ, Merz CNB, Pepine CJ, *et al*. The economic burden of angina in women with suspected
24388 ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and
25389 Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. *Circulation*. 2006;114:894–
26390 904. doi: 10.1161/CIRCULATIONAHA.105.609990
27391
28391
29
30392 9 Gulati M, Khan N, George M, *et al*. Ischemia with no obstructive coronary artery disease (INOCA):
31393 A patient self-report quality of life survey from INOCA international. *Int J Cardiol*. 2023;371:28–
32393 39. doi: 10.1016/j.ijcard.2022.09.047
33394
34
35395 10 Takahashi T, Samuels BA, Li W, *et al*. Safety of Provocative Testing With Intracoronary
36396 Acetylcholine and Implications for Standard Protocols. *J Am Coll Cardiol*. 2022;79:2367–78. doi:
37396 10.1016/j.jacc.2022.03.385
38397
39
40398 11 Douglas PS, Hoffmann U, Patel MR, *et al*. Outcomes of anatomical versus functional testing for
41399 coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516
42399
43
44400 12 Udelson JE, Kelsey MD, Nanna MG, *et al*. Deferred Testing in Stable Outpatients With Suspected
45401 Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized
46402 Clinical Trial. *JAMA Cardiol*. Published Online First: 23 August 2023. doi:
47402 10.1001/jamacardio.2023.2614
48403
49
50404 13 Gulati M, Levy PD, Mukherjee D, *et al*. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR
51405 Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of
52405 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
53406 *Circulation*. 2021;144:e368–454. doi: 10.1161/CIR.0000000000001029
54407
55
56
57408 14 Knuuti J, Wijns W, Saraste A, *et al*. 2019 ESC Guidelines for the diagnosis and management of
58409 chronic coronary syndromes. *Eur Heart J*. 2020;41:407–77. doi: 10.1093/eurheartj/ehz425
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

- 15 Jordan KP, Timmis A, Croft P, *et al.* Prognosis of undiagnosed chest pain: linked electronic health record cohort study. *BMJ*. 2017;357:j1194. doi: 10.1136/bmj.j1194
- 16 Jespersen L, Hvelplund A, Abildstrøm SZ, *et al.* Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. *Eur Heart J*. 2012;33:734–44. doi: 10.1093/eurheartj/ehr331
- 17 Gulati M, Cooper-DeHoff RM, McClure C, *et al.* Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med*. 2009;169:843–50. doi: 10.1001/archinternmed.2009.50
- 18 Fordyce CB, Douglas PS, Roberts RS, *et al.* Identification of Patients With Stable Chest Pain Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2017;2:400–8. doi: 10.1001/jamacardio.2016.5501
- 19 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515
- 20 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3
- 21 Sharaf B, Wood T, Shaw L, *et al.* Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. *Am Heart J*. 2013;166:134–41. doi: 10.1016/j.ahj.2013.04.002
- 22 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome Evaluation). *J Am Heart Assoc*. 2020;9:e013234. doi: 10.1161/JAHA.119.013234
- 23 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*. 2015;350:g7594. doi: 10.1136/bmj.g7594
- 24 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516
- 25 Bairey Merz CN, Pepine CJ, Walsh MN, *et al.* Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. *Circulation*. 2017;135:1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534

1
2
3 445 26 Maddox TM, Stanislawski MA, Grunwald GK, *et al.* Nonobstructive coronary artery disease and
4 risk of myocardial infarction. *JAMA*. 2014;312:1754–63. doi: 10.1001/jama.2014.14681
5 446
6
7 447 27 Bugiardini R, Bairey Merz CN. Angina with “normal” coronary arteries: a changing philosophy.
8 *JAMA*. 2005;293:477–84. doi: 10.1001/jama.293.4.477
9 448
10
11 449 28 Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with anginalike chest pain
12 and normal coronary angiographic findings. *J Am Coll Cardiol*. 1995;25:1013–8. doi:
13 10.1016/0735-1097(94)00519-v
14 451
15
16 452 29 Kaski JC, Rosano GM, Collins P, *et al.* Cardiac syndrome X: clinical characteristics and left
17 ventricular function. Long-term follow-up study. *J Am Coll Cardiol*. 1995;25:807–14. doi:
18 10.1016/0735-1097(94)00507-M
19 454
20
21 455 30 Sharaf BL, Pepine CJ, Kerensky RA, *et al.* Detailed angiographic analysis of women with
22 suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women’s Ischemia
23 Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). *Am J Cardiol*. 2001;87:937–
24 457 41; A3. doi: 10.1016/s0002-9149(01)01424-2
25 458
26
27 459 31 Kenkre TS, Malhotra P, Johnson BD, *et al.* Ten-Year Mortality in the WISE Study (Women’s
28 Ischemia Syndrome Evaluation). *Circ Cardiovasc Qual Outcomes*. 2017;10:e003863. doi:
29 460 10.1161/CIRCOUTCOMES.116.003863
30 461
31
32 462 32 Sedlak TL, Lee M, Izadnegahdar M, *et al.* Sex differences in clinical outcomes in patients with
33 stable angina and no obstructive coronary artery disease. *Am Heart J*. 2013;166:38–44. doi:
34 463 10.1016/j.ahj.2013.03.015
35 464
36
37 465 33 Smilowitz NR, Prasad M, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 2-
38 Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review. *J Am*
39 466 *Coll Cardiol*. 2023;82:1264–79. doi: 10.1016/j.jacc.2023.06.044
40 467
41
42 468 34 Moreau P, d’Uscio LV, Lüscher TF. Structure and reactivity of small arteries in aging. *Cardiovasc*
43 *Res*. 1998;37:247–53. doi: 10.1016/s0008-6363(97)00225-3
44 469
45
46 470 35 Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and
47 treatment. *Coron Artery Dis*. 2018;29:161–7. doi: 10.1097/MCA.0000000000000598
48 471
49
50 472 36 Gan T, Hu J, Liu W, *et al.* Causal Association Between Anemia and Cardiovascular Disease: A 2-
51 Sample Bidirectional Mendelian Randomization Study. *J Am Heart Assoc*. 2023;12:e029689. doi:
52 10.1161/JAHA.123.029689
53 474
54
55 475 37 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated
56 with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.
57 *Circulation*. 2003;107:223–5. doi: 10.1161/01.cir.0000052622.51963.fc
58 477
59
60 478 38 Herzog CA, Asinger RW, Berger AK, *et al.* Cardiovascular disease in chronic kidney disease. A

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Superior (ABES)

- clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int.* 2011;80:572–86. doi: 10.1038/ki.2011.223
- 39 Liu F, Ma G, Tong C, *et al.* Elevated blood urea nitrogen-to-creatinine ratio increased the risk of Coronary Artery Disease in patients living with type 2 diabetes mellitus. *BMC Endocr Disord.* 2022;22:50. doi: 10.1186/s12902-022-00954-3
- 40 Kirtane AJ, Leder DM, Waikar SS, *et al.* Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. *J Am Coll Cardiol.* 2005;45:1781–6. doi: 10.1016/j.jacc.2005.02.068
- 41 He X, Liu C, Chen Y, *et al.* Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. *Can J Cardiol.* 2018;34:999–1003. doi: 10.1016/j.cjca.2018.03.013
- 42 Wannamethee SG, Shaper AG, Lennon L, *et al.* Mild hyponatremia, hypernatremia and incident cardiovascular disease and mortality in older men: A population-based cohort study. *Nutr Metab Cardiovasc Dis NMCD.* 2016;26:12–9. doi: 10.1016/j.numecd.2015.07.008
- 43 Ahn SY, Park YS, Lee SW, *et al.* Association Between Small Decrease in Serum Sodium Concentration within the Normal Range and All-Cause and Cardiovascular Mortality in Elderly Adults over 5 Years. *J Am Geriatr Soc.* 2016;64:510–7. doi: 10.1111/jgs.13937
- 44 Sajadieh A, Binici Z, Mouridsen MR, *et al.* Mild hyponatremia carries a poor prognosis in community subjects. *Am J Med.* 2009;122:679–86. doi: 10.1016/j.amjmed.2008.11.033
- 45 Doust JA, Pietrzak E, Dobson A, *et al.* How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *BMJ.* 2005;330:625. doi: 10.1136/bmj.330.7492.625
- 46 McKie PM, Rodeheffer RJ, Cataliotti A, *et al.* Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertens Dallas Tex* 1979. 2006;47:874–80. doi: 10.1161/01.HYP.0000216794.24161.8c
- 47 Wang TJ, Larson MG, Levy D, *et al.* Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med.* 2004;350:655–63. doi: 10.1056/NEJMoa031994
- 48 Rosenberg J, Schou M, Gustafsson F, *et al.* Prognostic threshold levels of NT-proBNP testing in primary care. *Eur Heart J.* 2009;30:66–73. doi: 10.1093/eurheartj/ehn525
- 49 Kistorp C, Raymond I, Pedersen F, *et al.* N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA.* 2005;293:1609–16. doi: 10.1001/jama.293.13.1609
- 50 Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms, Evaluation, and

1
2
3 513 Clinical Significance. *JACC Cardiovasc Imaging*. 2017;10:65–77. doi:
4 514 10.1016/j.jcmg.2016.11.003
5
6
7 515 51 Krahm AD, Manfreda J, Tate RB, *et al*. The natural history of atrial fibrillation: incidence, risk
8 516 factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med*. 1995;98:476–84. doi:
9 517 10.1016/S0002-9343(99)80348-9
10
11
12 518 52 Marsan NA, Maffessanti F, Tamborini G, *et al*. Left atrial reverse remodeling and functional
13 519 improvement after mitral valve repair in degenerative mitral regurgitation: a real-time 3-
14 520 dimensional echocardiography study. *Am Heart J*. 2011;161:314–21. doi:
15 521 10.1016/j.ahj.2010.10.029
16
17
18 522 53 Lloyd-Jones DM, Wang TJ, Leip EP, *et al*. Lifetime risk for development of atrial fibrillation: the
19 523 Framingham Heart Study. *Circulation*. 2004;110:1042–6. doi:
20 524 10.1161/01.CIR.0000140263.20897.42
21
22
23 525 54 Bozkurt B, Coats AJS, Tsutsui H, *et al*. Universal definition and classification of heart failure: a
24 526 report of the Heart Failure Society of America, Heart Failure Association of the European Society
25 527 of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition
26 528 of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of
27 529 India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur*
28 530 *J Heart Fail*. 2021;23:352–80. doi: 10.1002/ejhf.2115
29
30
31 531 55 Heidenreich PA, Bozkurt B, Aguilar D, *et al*. 2022 AHA/ACC/HFSA Guideline for the
32 532 Management of Heart Failure: A Report of the American College of Cardiology/American Heart
33 533 Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e895–1032.
34 534 doi: 10.1161/CIR.0000000000001063
35
36
37
38
39
40 535
41
42
43
44 536

Figure and table

537 **Figure 1. Flowchart of study participation.** CAD, coronary artery disease.
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Superior (ABES)






Figure 2. Variable Selection Based on LASSO Regression. (A) Variation Characteristics of Variable Coefficients; (B) Selection Process of Optimal λ Value in LASSO Regression Model Using Cross-

1
2
3
4 542 Validation.

5
6
7 A



30 B



543
544
545 **Figure 3. Nomogram for predicting the probability of 1-, 2-, and 3-year event-free survival of**
546 **ANOCA patients as assessed by coronary angiography. ALT, alanine transaminase; AST, aspartate**

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

transaminase; LVEF, left ventricular ejection fraction.




Figure 4. Receiver operating characteristic curve for the 1-, 2-, and 3-year primary endpoints of the nomogram in the training set (A) and validation set (B). AUC, area under receiver operating characteristic curve.




Figure 5. Calibration plot of predicted 1-, 2-, and 3-year event-free survival based on the nomogram in the training set and validation set. (A–C) Training set; (D–F) Validation set.




Figure 6. Decision curve analysis of the nomogram in the training cohort (A) and validation cohort (B). The x-axis represents the threshold probability, and the y-axis measures the net benefit. The left-slanting straight line shows the net benefit of treating all patients. The bottom horizontal gray line represents the net benefit of not treating any patients. The curve in the middle represents the nomogram.





Figure 7. Kaplan-Meier curves for 1-year, 2-year, and 3-year event-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



Supplementary Table 1. Clinical data of the total population, training set and validation set.


Supplementary Figure 1. Event-free survival probability of different adverse events in the total population.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 2. Kaplan-Meier curves for 1-year, 2-year, and 3-year MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



For peer review only


Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).





BMJ Open first published as 10.1136/bmjopen-2024-028261 on May 2025. Downloaded from <http://bmjopen.bmj.com/> on June 8, 2025 at Agence Bibliographique de l'Enseignement Supérieur (AES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44








A



BMJ Open

Page 38 of 45



9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35


36

37



38

39


40





E




F






Risk Low High



Number at risk

Risk					
	0	400	800	1200	1600
Low	3946	2875	1906	927	66
High	506	353	189	71	10



Number at risk

Risk					
	0	400	800	1200	1600
Low	1336	993	648	325	34
High	146	92	51	20	0

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplement

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
Female, n (%)	3462 (58.3%)	2609 (58.6%)	853 (57.6%)	0.499
Age, years	43.6 (10.8)	43.7 (10.9)	43.5 (10.6)	0.563
Smoking, n (%)	1509 (25.4%)	1126 (25.3%)	383 (25.8%)	0.698
Drinking, n (%)	1883 (31.7%)	1415 (31.8%)	468 (31.6%)	0.909
Hypertension, n (%)	3698 (62.3%)	2802 (62.9%)	896 (60.5%)	0.094
Diabetes mellitus, n (%)	1123 (18.9%)	846 (19.0%)	277 (18.7%)	0.820
Diabetic complications, n (%)	19 (0.32%)	13 (0.29%)	6 (0.40%)	0.595
Dyslipidemia, n (%)	582 (9.81%)	423 (9.50%)	159 (10.7%)	0.185
CKD, n (%)	202 (3.40%)	151 (3.39%)	51 (3.44%)	0.993
SBP, mmHg	136 (19.8)	136 (19.9)	136 (19.7)	0.340
DBP, mmHg	81.9 (12.3)	81.9 (12.4)	81.8 (11.9)	0.757
Heart rate, beats/min	73.8 (15.2)	73.8 (13.9)	73.9 (18.5)	0.798
WBC, 10 ⁹ /L	6.67 (2.03)	6.68 (2.01)	6.67 (2.11)	0.969
Hemoglobin, g/L	136 (16.6)	136 (16.6)	136 (16.4)	0.881
Urea, mmol/L	6.09 (2.68)	6.09 (2.72)	6.08 (2.57)	0.831
Serum creatinine, µmol/L	65.9 [55.7; 79.8]	66.2 [55.7; 79.7]	65.4 [55.5; 80.0]	0.748
Uric acid, µmol/L	335 (100)	335 (101)	335 (99.0)	0.889
Serum sodium, mmol/L	142 (3.51)	142 (3.32)	142 (4.01)	0.829
Serum potassium, mmol/L	4.12 (0.56)	4.12 (0.47)	4.13 (0.76)	0.649
Serum chloride, mmol/L	106 (3.37)	106 (3.42)	106 (3.21)	0.515
Anion gap, mmol/L	14.0 (2.40)	13.9 (2.40)	14.0 (2.42)	0.844

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
Total protein, g/L	68.2 (6.41)	68.2 (6.37)	68.2 (6.54)	0.968
Albumin, g/L	42.4 (3.88)	42.4 (3.87)	42.3 (3.91)	0.406
Globulin, g/L	25.9 (4.19)	25.8 (4.16)	25.9 (4.30)	0.353
ALT, U/L	17.7 [13.0; 24.7]	17.8 [13.1; 24.8]	17.6 [12.6; 24.5]	0.169
AST, U/L	17.7 [14.6; 21.6]	17.8 [14.6; 21.6]	17.5 [14.6; 21.5]	0.341
ALT/AST ratio	1.06 (0.41)	1.05 (0.41)	1.07 (0.42)	0.157
Total bilirubin, µmol/L	13.6 (6.67)	13.6 (6.81)	13.4 (6.23)	0.257
Indirect Bilirubin, µmol/L	9.63 (4.69)	9.67 (4.75)	9.51 (4.53)	0.242
Direct Bilirubin, µmol/L	3.40 [2.30; 4.60]	3.40 [2.30; 4.60]	3.40 [2.40; 4.60]	0.611
Alkaline phosphatase, U/L	76.5 (23.6)	76.5 (23.6)	76.6 (23.7)	0.820
Total cholesterol, mmol/L	4.75 (1.12)	4.75 (1.13)	4.74 (1.08)	0.919
Triglycerides, mmol/L	1.63 (1.11)	1.62 (1.11)	1.65 (1.10)	0.485
HDL-C, mmol/L	1.22 (0.31)	1.22 (0.32)	1.20 (0.30)	0.083
LDL-C, mmol/L	2.97 (0.88)	2.97 (0.88)	2.98 (0.87)	0.498
VLDL-C, mmol/L	0.56 (0.37)	0.56 (0.39)	0.56 (0.30)	0.627
Troponin I, ng/ml	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.536
NT-proBNP, ng/L	83.7 [35.1; 266]	83.0 [34.3; 265]	86.7 [38.0; 269]	0.415
CKMB, U/L	12.1 [9.30; 14.7]	12.0 [9.24; 14.7]	12.3 [9.30; 14.7]	0.529
D-Dimer, µg/L	276 [2.34; 434]	274 [1.78; 427]	282 [4.65; 457]	0.110
Glucose, mmol/L	6.81 (2.48)	6.82 (2.45)	6.78 (2.56)	0.579
Left atrial diameter, mm	38.7 (5.24)	38.7 (5.28)	38.6 (5.11)	0.331


Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
LVEDD, mm	47.4 (4.46)	47.4 (4.51)	47.3 (4.28)	0.373
LVESD, mm	26.9 (5.62)	26.9 (5.65)	27.0 (5.52)	0.737
RVEDD, mm	20.8 (3.37)	20.7 (3.61)	20.8 (2.53)	0.623
LVEF, %	61.7 (6.75)	61.7 (6.77)	61.6 (6.70)	0.486
Event-free survival time, days	635 (403)	633 (402)	641 (406)	0.512
Death, n (%)	106 (1.79%)	78 (1.75%)	28 (1.89%)	0.816
MI endpoint, n (%)	33 (0.56%)	21 (0.47%)	12 (0.81%)	0.189
Stroke endpoint, n (%)	11 (0.19%)	6 (0.13%)	5 (0.34%)	0.156
MACE, n (%)	82 (1.38%)	64 (1.44%)	18 (1.21%)	0.611
Primary endpoint, n (%)	145 (2.44%)	105 (2.36%)	40 (2.70%)	0.523

CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; CKMB, creatine kinase-MB; LVEDD, left ventricular-end-diastolic diameter; LVESD, left ventricular-end-systolic diameter; RVEDD, right ventricular-end-diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MACE, major adverse cardiovascular events.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Supérieur (ABES).

Supplementary Figure 1. Event-free survival probability of different adverse events in the total population



Supplementary Figure 2. Kaplan-Meier curves for 1-year, 2-year, and 3-year MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).



BMJ Open

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-092614.R1
Article Type:	Original research
Date Submitted by the Author:	06-Mar-2025
Complete List of Authors:	<p>Zhu, Lei; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology</p> <p>Xue, Zheng-Kai; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology</p> <p>Wu, Xue; University of California San Francisco, Institute for Global Health Sciences</p> <p>Zhang, JingKun; University of California San Francisco, Cardiovascular Research Institute</p> <p>Hu, Su-Tao; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology</p> <p>Zhang, Yu-Kun; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology</p> <p>Gu, Tian-Shu; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology</p> <p>Liu, Tong; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology</p> <p>Rha, Seung-Woon; Korea University Guro Hospital, Cardiovascular Center</p> <p>Chen, Kang-Yin; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Angina Pectoris, Coronary heart disease < CARDIOLOGY, Prognosis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1

2

3

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Authors: Lei Zhu¹, Zheng-Kai Xue¹, Xue Wu², Jing-Kun Zhang³, Su-Tao Hu¹, Yu-Kun Zhang¹, Tian-Shu Gu¹, Tong Liu¹, Seung-Woon Rha⁴, Kang-Yin Chen^{1*}

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Affiliations: ¹ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

² Institute for Global Health Sciences, University of California, San Francisco, CA, USA

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

³ Cardiovascular Research Institute, University of California San Francisco, CA, USA

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

⁴ Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

*Corresponding author: Kang-Yin Chen, MD, PhD, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China (chenkangyin@vip.126.com)

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Word count: 3074

Abstract

Objectives

To develop and validate a risk prediction model for adverse outcomes in patients with angina with nonobstructive coronary arteries (ANOCA) confirmed by invasive coronary angiography.

Design

Retrospective cohort study.

Setting

A tertiary cardiovascular care center in East Asia.

Participants

From 17,816 consecutive patients undergoing coronary angiography for suspected coronary artery disease, 5,934 met ANOCA criteria after rigorous exclusion: (1) significant stenosis ($\geq 50\%$ luminal narrowing), (2) established coronary artery disease history, (3) incomplete baseline/follow-up data, (4) non-cardiovascular life-limiting conditions.

primary and secondary outcome measures

The primary outcome was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or coronary-artery bypass grafting (CABG). The secondary outcome was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG.

Results

The derivation cohort (n=4,452) and validation cohort (n=1,482) demonstrated comparable baseline

1
2
3
4 36 characteristics. The nomogram incorporated eight prognosticators: age, hemoglobin, serum urea,
5
6
7 37 serum sodium, ALT/AST ratio, NT-proBNP, left atrial diameter, and LVEF. The prediction model
8
9
10 38 showed robust discrimination for primary endpoint (derivation AUC: 0.82 [1-year], 0.90 [2-year], 0.89
11
12 39 [3-year]; validation AUC: 0.75, 0.77, 0.78). Calibration plots revealed close alignment between
13
14
15 40 predicted and actual event-free survival probabilities in both cohorts. Risk stratification identified two
16
17
18 41 distinct prognostic groups with significant survival differences (log-rank $p < 0.0001$).

21 42 **Conclusions**

25 43 This predictive model integrates routinely available clinical parameters to accurately stratify mortality
26
27
28 44 and cardiovascular risk in ANOCA patients, providing a potential valuable decision-support tool for
29
30
31 45 personalized therapeutic strategies.

36 47 **Strengths and limitations of this study**

- 39 48
- 41 49 • This study utilized a large sample size (n=5934) with rigorous internal validation through
42 training and testing cohorts.
 - 44 50 • Leveraged LASSO-penalized Cox regression with 10-fold cross-validation to optimize model
45 generalizability.
 - 47 51 • The nomogram integrates routinely available clinical variables, enhancing clinical applicability.
 - 52 52 • Limitations include the retrospective design, which may introduce selection bias.
 - 53 53 • Data were derived from a single center, potentially limiting generalizability.
 - 54 54
 - 55 55
 - 56
 - 57
 - 58
 - 59
 - 60

Key word

Angina, coronary artery disease, MINOCA, prognosis, nomogram.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Backgrounds

Chest pain is a common symptom among patients seeking medical services, often raising concerns about potentially life-threatening conditions such as coronary artery disease (CAD) [1,2]. Timely and accurate diagnostic assessments, including electrocardiography, coronary computed tomography angiography, and coronary angiography, are frequently recommended for individuals presenting with chest pain to rule out severe conditions such as myocardial infarction (MI) [3,4]. However, in the cohort of patients undergoing diagnostic workup, approximately half exhibit nonobstructive coronary arteries (stenosis less than 50%)[5,6], a condition known as angina with nonobstructive coronary arteries (ANOCA) [7].

ANOCA patients often seek medical care due to symptoms and undergo repetitive invasive examinations, leading to significant healthcare resource utilization and imposing individual burdens and additional risks [8–10]. In a randomized controlled trial involving over 10,000 patients suspected of CAD with intermediate pretest likelihood, only approximately 12% of them yielded a positive result in the final coronary artery functional tests [11]. Patients with a low pretest probability exhibit an exceedingly low positivity rate in diagnostic workup and experience fewer adverse outcomes [12]. Therefore, clinical guidelines recommend delaying diagnostic testing for patients at low risk for CAD[13,14]. However, patients without obstructive coronary arteries confirmed by coronary angiography (CAG) or coronary computed tomography angiography (CCTA) have been observed to experience more adverse outcomes compared to the general population[15–17]. Identifying high-risk individuals in ANOCA patients remains a challenge.

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

There is limited research on predicting adverse outcomes in ANOCA patients confirmed through CAG or CCTA. Some studies have validated the utility of specific pretest indicators, such as age, sex, and traditional cardiovascular disease risk factors(e.g., hypertension), to identify low-risk ANOCA patients [18]. However, several investigations have shown that specific blood biomarkers, including high-sensitivity troponin and lower HDL-C levels, operate as independent predictive factors for poor prognosis in ANOCA patients, adding prognostic value[19]. To date, comprehensive studies that screen noninvasive indicators and develop a prognostic model are lacking, and most previous studies are reliant on data derived from the Women's Ischemia Syndrome Evaluation (WISE) study[19–21], which exclusively includes female participants. One study also used WISE data to validate the effectiveness of some risk scores originally designed for other populations, such as the ASCVD score, in predicting adverse outcomes in ANOCA patients, but the results showed suboptimal performance[22]. Therefore, it is necessary to develop a predictive model based on non-invasive indicators to forecast adverse outcomes in ANOCA patients of both sexes. This study aims to bridge this gap to optimize clinical decision-making and patient management.

Method

Study Population

This is a retrospective cohort study that consecutively enrolled patients who presented with suspected

1
2
3
4 101 symptoms of CAD and underwent coronary angiography at the Department of Cardiology or
5
6
7 102 Emergency Department of the Second Hospital of Tianjin Medical University between January 2019
8
9
10 103 and June 2023. The Second Hospital of Tianjin Medical University is a cardiac center serving the
11
12 104 northern Chinese city of Tianjin and its surrounding regions. This study adheres to the principles
13
14
15 105 outlined in the TRIPOD statement [23].

16
17
18 106
19
20 107 ANOCA patients were defined as angina with nonobstructive epicardial coronary arteries (stenosis
21
22
23 108 <50%), adhering to current expert consensus[7]. Patients meeting the following criteria were excluded
24
25
26 109 from the study: (1) patients with acute coronary syndrome or obstructive coronary arteries (defined as
27
28
29 110 a luminal stenosis of $\geq 50\%$ in a major epicardial coronary artery[7,24]); (2) patients with a prior
30
31 111 diagnosis of CAD, history of percutaneous coronary intervention (PCI), or coronary artery bypass
32
33
34 112 grafting (CABG); (3) individuals with severe liver or kidney dysfunction, malignancies, or other non-
35
36
37 113 cardiovascular conditions significantly affecting life expectancy; (4) those with substantial missing
38
39
40 114 baseline data; and (5) patients lost to follow-up. This study received approval from the Ethics
41
42 115 Committee of the Second Hospital of Tianjin Medical University, with a waiver for written informed
43
44
45 116 consent granted for the retrospective use of fully anonymized clinical data (No. KY2025K008).

46
47
48 117
49
50
51 118 **Clinical Data Collection**

52
53
54
55 119 Patient data were retrospectively obtained from electronic medical records, including demographic
56
57
58 120 information, medical history, vital sign data, laboratory parameters, echocardiographic data, coronary
59
60

angiography findings and other relevant details.

Follow-Up and Endpoints

A dedicated follow-up team conducted systematic post-discharge surveillance through a standardized protocol, with scheduled assessments at 30 days, 3 months, 6 months, and annually thereafter. Data collection employed a multimodal approach: (1) comprehensive electronic health record review, (2) cross-referencing with regional death registries, (3) and telephone or email interviews. The observational window for this analysis was finalized on August 1, 2023. Two board-certified cardiologists (L.Z. and Z.K.X., each with >5 years clinical experience) independently evaluated all events using standardized diagnostic criteria[25,26]. For discrepancies in event classification, an adjudication committee comprising two senior interventional cardiologists (T.L. and K.Y.C., both with >20 years catheterization laboratory experience) conducted final arbitration through consensus review.

The primary endpoint was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or coronary-artery bypass grafting (CABG) during follow-up. The secondary endpoint was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG during follow-up. The composite endpoint was selected based on its established utility in prognostic studies of ANOCA [22,27–29].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical Analysis

For the small amount of missing data in smoking and alcohol consumption history, multiple imputation was performed using the MICE package (Multiple Imputation by Chained Equations package). To establish a reliable model, the entire study cohort was randomly stratified into two subsets, a training set and a validation set, with a ratio of 0.75 to 0.25, respectively. The training set was used to generate the predictive model, while the validation set was utilized for model internal validation.

Categorical variables were described as frequencies and percentages, with group differences assessed using the chi-square test or Fisher's exact test as applicable. Continuous variables were expressed as either the mean \pm standard deviation (SD) or median [interquartile range, IQR], and group comparisons were conducted using the t test or Kruskal–Wallis test as appropriate. Variables with VIF ≥ 5 were excluded prior to LASSO regression to mitigate multicollinearity. The variables selected through LASSO regression were incorporated into the Cox proportional hazards regression model, and a nomogram was generated based on the Cox regression analysis model. The discriminative ability of the predictive model was evaluated using AUC. The model's calibration was assessed through the calibration curve. Additionally, decision curve analysis was employed to evaluate the clinical utility of the nomogram.

The total score for each patient was calculated based on the nomogram, and the study population was stratified into high-risk and low-risk groups according to the score corresponding to the 3-year 95% event-free survival probability. Event-free survival for the high- and low-risk groups in the training

and validation sets was estimated by Kaplan–Meier method and compared with the log-rank test. All statistical analyses were performed with R software version 4.3.1 (R Foundation for Statistical Computing). All statistical tests were two- tailed, with a significance level set at $P < 0.05$.

Patient and public involvement

None.

Result

Study Population and Patient Characteristics

Out of a consecutive cohort of 17,816 patients who underwent coronary angiography for suspected coronary artery disease, 9,883 individuals with significant coronary artery stenosis and 1,816 patients with a documented history of coronary heart disease were excluded. An additional 131 individuals were excluded due to missing baseline or follow-up data, and 52 patients with severe conditions such as malignant tumors were also excluded. of the final analysis included 5,934 patients with negative coronary angiography results (**Figure 1**).

The mean age of the overall cohort was 43.6 ± 10.8 years, with 58.3% being female, and the median follow-up time was 631 [270, 972] days. Detailed baseline data are provided in **Supplementary Table 1**. During the follow-up period, 145 (2.44%) patients had primary endpoint events, 82 (1.38%) had MACE, 106 (1.79%) had all-cause death, 33 (0.56%) had MI, and 11 (0.19%) had a stroke. The

1
2
3
4 182 Kaplan-Meier method was employed to estimate the survival without various adverse events for the
5
6
7 183 total study population (**Supplementary Figure 1**).
8
9
10 184

11
12
13 185 **Nomogram built based on LASSO-COX regression**
14
15
16

17 186 The entire cohort was randomly divided into a training cohort consisting of 4,452 patients and a
18
19
20 187 validation cohort comprising 1,482 patients. There were no statistically significant differences in the
21
22
23 188 collected variables between these two groups (**Supplementary Table 1**). LASSO regression was
24
25 189 employed to select variables with the strongest correlation to the primary endpoint. As the
26
27
28 190 regularization parameter (λ) increased, certain coefficients were reduced to zero, effectively
29
30
31 191 eliminating those variables from the model (**Figure 2A**). We used a tenfold cross-validation approach
32
33
34 192 to identify the optimal model. Due to the relatively limited number of cases undergoing primary
35
36 193 endpoint events in the validation cohort (145), we employed the one standard error (1-se) rule, resulting
37
38
39 194 in eight selected variables (**Figure 2B**). These variables were incorporated into a Cox proportional
40
41
42 195 hazards regression model, with results presented in **Table 1**. All models satisfied proportional hazards
43
44
45 196 assumptions (global test $p=0.057$). A nomogram was developed based on the Cox regression model,
46
47 197 with the regression coefficients of these factors amalgamated into a scoring system, ranging from 0 to
48
49
50 198 100(**Figure 3**). For example, an 81-year-old male patient with a hemoglobin level of 92 g/L, serum
51
52
53 199 urea of 14.1 mmol/L, serum sodium of 145.6 mmol/L, an ALT/AST ratio of 1.68, NT-proBNP at 272
54
55 200 ng/L, left atrial diameter of 38.83 millimeters, and an LVEF of 62% received a total score of 115. The
56
57
58 201 1-year, 2-year and 3-year event-free survival rates were 99.5%, 96.2% and 89.0%, respectively.
59
60

Table 1. Prediction of event-free survival probability using the Cox proportional hazards regression model based on LASSO regression.

Variable	coefficients	z score	HR	95%CI	p value
Age	0.043	4.167	1.044	0.023, 0.063	<0.001
Hemoglobin	-0.015	-2.871	0.985	-0.026, -0.005	0.004
Urea	0.074	3.947	1.077	0.037, 0.111	<0.001
Serum sodium	-0.074	-5.694	0.929	-0.1, -0.049	<0.001
ALT/AST ratio	0.444	2.439	1.559	0.087, 0.8	0.015
NT-proBNP	0	2.094	1	0, 0	0.036
Left atrial diameter	0.076	5.959	1.079	0.051, 0.8	<0.001
LVEF	-0.022	-2.289	0.979	-0.04, -0.003	0.022

HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; AST, aspartate transaminase; LVEF, left ventricular ejection fraction.

Discrimination and calibration of the nomogram

The discriminative ability of the model was assessed by plotting receiver operating characteristic curves. In the training set, the AUC for 1-, 2-, and 3-year predictions was 0.82, 0.90, and 0.89, respectively. In the validation set, the corresponding AUC for 1-, 2-, and 3-year predictions were 0.75, 0.77, and 0.78, respectively (**figure 4**).

Figure 5 illustrates calibration plots for the models predicting 1-, 2-, and 3-year survival in both the training and validation datasets. In well-calibrated models, the points closely align with the ideal 45-degree line, indicating that predicted survival closely matches observed survival and demonstrating

1
2
3
4 217 good model calibration.
5
6

7 218

8
9
10
11 219 **Decision Curve**

12
13
14
15 220 Decision curve analysis was employed to evaluate the potential improvement in clinical outcomes
16
17 221 through nomogram-assisted decision-making for patients. As illustrated in **Figure 6**, the results reveal
18
19
20 222 that across a broad spectrum of threshold probabilities in both the training and testing cohorts, utilizing
21
22
23 223 the nomogram for predicting the 2-year or 3-year event-free survival probability offers a more
24
25 224 significant net benefit when compared to strategies of 'treat all' or 'treat none.' These findings
26
27
28 225 underscore the clinical utility of the nomogram.
29
30

31 226
32
33
34
35 227 **Risk stratification**

36
37
38
39 228 Considering that the study population consists of low-risk patients with non-obstructive coronary
40
41 229 artery stenosis, the threshold for further risk stratification was set at a higher event-free survival
42
43
44 230 probability, specifically a score of 104 points corresponding to the 95% 3-year event-free survival
45
46
47 231 probability as determined by the nomogram. Individuals scoring below this threshold were categorized
48
49
50 232 as low-risk, while those scoring equal to or above it were classified as high-risk. Kaplan-Meier curves
51
52 233 depicting event-free survival were created for the two risk groups in the training and validation sets
53
54
55 234 (**Figure 7**). Furthermore, MACE-event free survival of these groups is shown in **Supplementary**
56
57
58 235 **Figure 2**. These results consistently demonstrated the model's efficacy in patient risk stratification.
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

Discussion

This study focused on patients initially suspected of having CAD but who were found to have nonobstructive coronary arteries following coronary angiography. A wide range of variables, including demographic information, vital signs, laboratory parameters, and echocardiographic measurements, were meticulously examined. Ultimately, 8 key variables, namely age, hemoglobin levels, serum urea, serum sodium levels, ALT/AST ratio, NT-proBNP levels, left atrial diameter, and LVEF, were identified. The study successfully developed a nomogram to predict the probability of event-free survival for these patients, demonstrating excellent discriminatory and calibration abilities in both the training and validation sets. The utilization of this predictive model in clinical practice empowers healthcare providers to conduct more precise risk stratification, particularly for individuals initially classified as low-risk, thereby improving diagnostic, management, and treatment strategies and ultimately enhancing patient outcomes.

In clinical practice, a substantial number of patients with potential cardiac issues, such as chest pain, actively seek medical attention in both outpatient and emergency department settings. In the United Kingdom, for instance, approximately 1-2% of adults consult primary care facilities when experiencing chest pain for the first time [15]. Similarly, millions of individuals in the United States undergo stress tests in outpatient clinics each year for undiagnosed heart conditions [30]. However, research has

1
2
3
4 256 consistently shown that following diagnostic assessments like coronary angiography, approximately
5
6
7 257 50% of patients do not exhibit obstructive coronary artery stenosis [5,16,24,31]. Traditionally, such
8
9
10 258 patients were often considered to have a favorable prognosis and no significant cardiac conditions ,
11
12 259 potentially resulting in the omission of further diagnostic measures and therapeutic interventions [32–
13
14
15 260 34]. However, recent research has indicated that these patients face a significantly elevated risk of
16
17
18 261 adverse outcomes compared to the general population. The WISE study revealed that at over a 10-year
19
20 262 follow-up, patients without obstructive coronary stenosis on coronary angiography had rates of
21
22
23 263 cardiovascular death and MI of 6.7% and 12.8%, respectively, underscoring the heightened risk among
24
25
26 264 female ANOCA patients [21,35,36]. Other studies have also demonstrated that ANOCA patients,
27
28
29 265 regardless of their gender, face an increased risk of experiencing CAD-related outcomes compared to
30
31 266 the general population[16,31,37].
32
33
34 267
35
36
37 268 Our findings from this study indicate that ANOCA patients tend to be younger, with an average age of
38
39 269 43.6 years, and a higher proportion of them are female (58.3%) [7]. During a median follow-up period
40
41
42 270 of 2 years, the rates of all-cause death, MI, and stroke were 1.79%, 0.56%, and 0.19%, respectively.
43
44
45 271 These findings align with a previous study reporting 1-year MI rates ranging from 0.11% to 0.59% and
46
47
48 272 1-year mortality rates ranging from 1.38% to 2.3% [31]. Our research further supports the
49
50 273 characterization of ANOCA patients and provides additional evidence of their elevated risk for adverse
51
52
53 274 outcomes across diverse populations.
54
55
56 275
57
58 276 While clinical guidelines suggest risk stratification of chest pain patients and deferring testing for those
59
60

with a low likelihood of CAD, this strategy may inadvertently exclude high-risk ANOCA patients who require further assessment and appropriate therapeutic interventions [13,14]. As highlighted in a recent review, a significant proportion of ANOCA patients (ranging from 75% to 90%) exhibit various underlying causes, such as coronary microvascular dysfunction (CMD), microvascular spasm, endothelial dysfunction, epicardial coronary spasm, and/or myocardial bridging [7,38], emphasizing the critical importance of identifying high-risk ANOCA patients to optimize their further management.

Current research on factors related to adverse outcomes in the ANOCA population is limited. One study attempted to develop a risk tool for chest pain patients with normal coronary arteries to predict favorable outcomes. This tool comprised 10 variables, including age, gender, and the presence of conditions like hypertension, diabetes, or dyslipidemia. However, it is important to note that this study solely relied solely on pretest clinical data and accessed coronary arteries through coronary CTA [18]. In contrast, our predictive model incorporated pre-test indicators, including demographic variables and medical history, with age being one of the key factors. Age is a variable included in many traditional CAD prediction models because it is easily obtainable and reflects the aging of the entire cardiovascular system, including increased arterial stiffness and decreased vascular endothelial function [39,40].

Previous studies have also indicated that several blood biomarkers are associated with unfavorable outcomes in ANOCA patients, including lower levels of HDL-C, elevated levels of soluble urokinase-type plasminogen activator receptor, and high-sensitivity troponin [19,20]. However, none of these

1
2
3
4 298 studies conducted comprehensive screening of clinical variables or developed a predictive model.
5
6
7 299 After a thorough screening of blood biomarkers, our predictive model incorporated hemoglobin, serum
8
9
10 300 urea, serum sodium and NT-proBNP, which are rarely reported to be associated with adverse outcomes
11
12 301 in ANOCA patients. Anemia, for example, is a common pathological condition involved in the
13
14
15 302 occurrence and development of CAD and heart failure through various mechanisms [41]. It
16
17
18 303 significantly increases the risk of developing CAD and heart failure and is associated with adverse
19
20 304 outcomes in these patients [42,43]. Serum urea reflects renal function, which is a crucial factor
21
22
23 305 influencing the cardiovascular system [44]. Previous research has shown that an elevated serum urea
24
25
26 306 levels increase the risk of CAD and serve as a predictive factors for adverse outcomes in CAD and
27
28
29 307 heart failure patients [45,46]. The role of serum sodium in cardiovascular disease is still not fully
30
31 308 understood, but several studies have indicated that even mild reductions in serum sodium, even within
32
33
34 309 the normal range, are associated with higher all-cause mortality and cardiovascular mortality in elderly
35
36
37 310 individuals or the general population [47–50]. The underlying mechanisms behind this association
38
39 311 require further research. NT-proBNP is a widely recognized marker for heart failure and exhibits
40
41
42 312 strong predictive capabilities for the prognosis of heart failure patients [51]. Previous studies have also
43
44
45 313 demonstrated its ability to predict cardiovascular events and mortality even in community-dwelling or
46
47
48 314 elderly populations without heart failure [52–55].
49
50 315
51
52
53 316 Our predictive model also considered echocardiographic parameters. Echocardiography is a
54
55
56 317 noninvasive, easily performed, and cost-effective imaging technique that provides comprehensive
57
58 318 insights into cardiac structure and function. In our model, left atrial diameter and LVEF were included.
59
60

Left atrial enlargement is closely associated with conditions like atrial fibrillation and heart failure, and factors such as hypertension and mitral valve diseases can also lead to left atrial enlargement. It is commonly regarded as a biomarker for adverse cardiovascular outcomes [56–59]. The LVEF serves as one of the diagnostic and classificatory criteria for heart failure, with the latter often signifying the advanced stage of diverse cardiac ailments and indicates an unfavorable prognosis [60,61].

Limitations

This study has several limitations. First, the retrospective design precludes control of treatment strategies and introduces potential selection bias. Second, the study population consisted entirely of individuals from northern China, so caution should be exercised when generalizing the findings of this study to other populations. Third, the inability to subclassify ANOCA patients into those with versus without atherosclerosis represents an important limitation, as pathophysiological differences between these cohorts may contribute to population heterogeneity. However, this aligns with current guideline definitions, and future studies incorporating intracoronary imaging could refine risk stratification. Finally, while the predictive model developed from single-center data has not yet undergone external validation, internal validation confirmed its robust discrimination and calibration, indicating strong performance within the original cohort.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

In summary, we conducted a comprehensive evaluation of clinically accessible variables and successfully developed a predictive model for assessing adverse outcomes in angina patients with suspected CAD who do not exhibit obstructive coronary artery stenosis. This nomogram equips clinicians with a valuable tool for risk stratification in ANOCA patients, allowing for optimized management and treatment strategies aimed at improving patient outcomes.

List of abbreviations

- ANOCA, angina with nonobstructive coronary arteries
- ACU, areas under the curve
- ALT, alanine transaminase
- AST, aspartate transaminase
- LVEF, left ventricular ejection fraction
- CAD, coronary artery disease
- MI, myocardial infarction
- CAG, coronary angiography
- CCTA, coronary computed tomography angiography
- HDL-C, high-density lipoprotein cholesterol
- PCI, percutaneous coronary intervention

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

CABG, coronary-artery bypass grafting

MACE, major adverse cardiovascular events

Funding

This study was supported by the Key Project of Tianjin Natural Science Foundation (Grant Number: 21JCZDJC01080), Academic Backbone of “Clinical Talent Training and Climbing Plan” of Tianjin Medical University.

Data availability statement

The original data supporting the findings of this study can be obtained from the corresponding author upon reasonable request.

Contributors

L.Z. Conceptualization, Investigation, Methodology, Data curation, Software, Formal analysis, Visualization, Writing – original draft. Z.K.X. Investigation, Data curation, Formal analysis, Writing – review and editing. X.W. Methodology, Writing – review and editing. J.K.Z. Methodology, Writing

1
2
3
4 377 – review and editing. S.T.H. Data curation, Writing – review and editing. Y.K.Z. Data curation,
5
6
7 378 Writing – review and editing. T.S.G. Data curation, Writing – review and editing. T.L. Supervision,
8
9
10 379 Validation, Writing – review and editing. S.W.R. Supervision, Validation, Funding
11
12 380 acquisition, Writing – review and editing. K.Y.C. Conceptualization, Funding acquisition,
13
14
15 381 Project administration, Resources, Supervision, Writing – review and editing. All authors approved
16
17
18 382 the final manuscript. K.Y.C. is responsible for the overall content as guarantor.
19
20
21 383
22
23

24 384 **Competing interests**

25
26
27
28 385 This study received infrastructure support from Tianjin Medical University. The funding organization
29
30
31 386 played no role in study design, data collection, analysis, interpretation, manuscript preparation, or
32
33 387 publication decisions. All authors declare no additional competing interests.
34
35
36 388
37
38
39 389
40
41
42 390
43
44 391
45
46
47

48 392 **References**

49
50
51 393 1 Hoorweg BB, Willemsen RT, Cleef LE, *et al.* Frequency of chest pain in primary care, diagnostic
52 394 tests performed and final diagnoses. *Heart Br Card Soc.* 2017;103:1727–32. doi: 10.1136/heartjnl-
53 395 2016-310905
54
55
56 396 2 Tsao CW, Aday AW, Almarzooq ZI, *et al.* Heart Disease and Stroke Statistics-2022 Update: A
57 397 Report From the American Heart Association. *Circulation.* 2022;145:e153–639. doi:
58 398 10.1161/CIR.0000000000001052
59 399
60

- 3 Virani SS, Newby LK, Arnold SV, *et al.* 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline
for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart
Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines.
Circulation. 2023;148:e9–119. doi: 10.1161/CIR.0000000000001168
- 4 Fihn SD, Gardin JM, Abrams J, *et al.* 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline
for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive
Summary: A Report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines, and the American College of Physicians, American
Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for
Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation.*
2012;126:3097–137. doi: 10.1161/CIR.0b013e3182776f83
- 5 Patel MR, Peterson ED, Dai D, *et al.* Low diagnostic yield of elective coronary angiography. *N
Engl J Med.* 2010;362:886–95. doi: 10.1056/NEJMoa0907272
- 6 Rahman H, Corcoran D, Aetesam-Ur-Rahman M, *et al.* Diagnosis of patients with angina and non-
obstructive coronary disease in the catheter laboratory. *Heart Br Card Soc.* 2019;105:1536–42.
doi: 10.1136/heartjnl-2019-315042
- 7 Samuels BA, Shah SM, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 1-
Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review. *J Am Coll Cardiol.*
2023;82:1245–63. doi: 10.1016/j.jacc.2023.06.043
- 8 Shaw LJ, Merz CNB, Pepine CJ, *et al.* The economic burden of angina in women with suspected
ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and
Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. *Circulation.* 2006;114:894–
904. doi: 10.1161/CIRCULATIONAHA.105.609990
- 9 Gulati M, Khan N, George M, *et al.* Ischemia with no obstructive coronary artery disease (INOCA):
A patient self-report quality of life survey from INOCA international. *Int J Cardiol.* 2023;371:28–
39. doi: 10.1016/j.ijcard.2022.09.047
- 10 Takahashi T, Samuels BA, Li W, *et al.* Safety of Provocative Testing With Intracoronary
Acetylcholine and Implications for Standard Protocols. *J Am Coll Cardiol.* 2022;79:2367–78. doi:
10.1016/j.jacc.2022.03.385
- 11 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for
coronary artery disease. *N Engl J Med.* 2015;372:1291–300. doi: 10.1056/NEJMoa1415516
- 12 Udelson JE, Kelsey MD, Nanna MG, *et al.* Deferred Testing in Stable Outpatients With Suspected
Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized
Clinical Trial. *JAMA Cardiol.* Published Online First: 23 August 2023. doi:
10.1001/jamacardio.2023.2614

1
2
3 434 13 Gulati M, Levy PD, Mukherjee D, *et al.* 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR
4 435 Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of
5 436 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
6 437 *Circulation*. 2021;144:e368–454. doi: 10.1161/CIR.0000000000001029
7
8
9
10 438 14 Knuuti J, Wijns W, Saraste A, *et al.* 2019 ESC Guidelines for the diagnosis and management of
11 439 chronic coronary syndromes. *Eur Heart J*. 2020;41:407–77. doi: 10.1093/eurheartj/ehz425
12
13 440 15 Jordan KP, Timmis A, Croft P, *et al.* Prognosis of undiagnosed chest pain: linked electronic health
14 441 record cohort study. *BMJ*. 2017;357:j1194. doi: 10.1136/bmj.j1194
15
16
17 442 16 Jespersen L, Hvelplund A, Abildstrøm SZ, *et al.* Stable angina pectoris with no obstructive
18 443 coronary artery disease is associated with increased risks of major adverse cardiovascular events.
19 444 *Eur Heart J*. 2012;33:734–44. doi: 10.1093/eurheartj/ehz331
20
21
22 445 17 Gulati M, Cooper-DeHoff RM, McClure C, *et al.* Adverse cardiovascular outcomes in women
23 446 with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome
24 447 Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med*. 2009;169:843–
25 448 50. doi: 10.1001/archinternmed.2009.50
26
27
28
29 449 18 Fordyce CB, Douglas PS, Roberts RS, *et al.* Identification of Patients With Stable Chest Pain
30 450 Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A
31 451 Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol*. 2017;2:400–8. doi:
32 452 10.1001/jamacardio.2016.5501
33
34
35 453 19 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble Urokinase-Type Plasminogen Activator
36 454 Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary
37 455 Artery Disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515
38
39
40 456 20 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women
41 457 with non-obstructive CAD on coronary CTA: pooled analysis from PROMISE and SCOT-HEART.
42 458 *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3
43
44
45 459 21 Sharaf B, Wood T, Shaw L, *et al.* Adverse outcomes among women presenting with signs and
46 460 symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart,
47 461 Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE)
48 462 angiographic core laboratory. *Am Heart J*. 2013;166:134–41. doi: 10.1016/j.ahj.2013.04.002
49
50
51
52 463 22 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted versus observed major adverse cardiac
53 464 event risk in women with evidence of ischemia and no obstructive coronary artery disease: A report
54 465 from WISE (women’s ischemia syndrome evaluation). *J Am Heart Assoc*. 2020;9:e013234. doi:
55 466 10.1161/JAHA.119.013234
56
57
58 467 23 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction
59 468 model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Superior (ABES)

2015;350:g7594. doi: 10.1136/bmj.g7594

- 24 Bairey Merz CN, Pepine CJ, Walsh MN, *et al.* Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. *Circulation*. 2017;135:1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534
- 25 K T, Js A, As J, *et al.* Fourth universal definition of myocardial infarction (2018). *J Am Coll Cardiol*. 2018;72. doi: 10.1016/j.jacc.2018.08.1038
- 26 Powers WJ, Rabinstein AA, Ackerson T, *et al.* Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association. *Stroke*. 2019;50:e344–418. doi: 10.1161/STR.0000000000000211
- 27 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: Pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3
- 28 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515
- 29 Johnson BD, Shaw LJ, Pepine CJ, *et al.* Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored women's ischaemia syndrome evaluation (WISE) study. *Eur Heart J*. 2006;27:1408–15. doi: 10.1093/eurheartj/ehl040
- 30 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516
- 31 Maddox TM, Stanislawski MA, Grunwald GK, *et al.* Nonobstructive coronary artery disease and risk of myocardial infarction. *JAMA*. 2014;312:1754–63. doi: 10.1001/jama.2014.14681
- 32 Bugiardini R, Bairey Merz CN. Angina with “normal” coronary arteries: a changing philosophy. *JAMA*. 2005;293:477–84. doi: 10.1001/jama.293.4.477
- 33 Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. *J Am Coll Cardiol*. 1995;25:1013–8. doi: 10.1016/0735-1097(94)00519-v
- 34 Kaski JC, Rosano GM, Collins P, *et al.* Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. *J Am Coll Cardiol*. 1995;25:807–14. doi: 10.1016/0735-1097(94)00507-M
- 35 Sharaf BL, Pepine CJ, Kerensky RA, *et al.* Detailed angiographic analysis of women with

1
2
3 503 suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women’s Ischemia
4 504 Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). *Am J Cardiol*. 2001;87:937–
5 505 41; A3. doi: 10.1016/s0002-9149(01)01424-2
6
7
8 506 36 Kenkre TS, Malhotra P, Johnson BD, *et al*. Ten-Year Mortality in the WISE Study (Women’s
9 507 Ischemia Syndrome Evaluation). *Circ Cardiovasc Qual Outcomes*. 2017;10:e003863. doi:
10 508 10.1161/CIRCOUTCOMES.116.003863
11
12
13 509 37 Sedlak TL, Lee M, Izadnegahdar M, *et al*. Sex differences in clinical outcomes in patients with
14 510 stable angina and no obstructive coronary artery disease. *Am Heart J*. 2013;166:38–44. doi:
15 511 10.1016/j.ahj.2013.03.015
16
17
18 512 38 Smilowitz NR, Prasad M, Widmer RJ, *et al*. Comprehensive Management of ANOCA, Part 2-
19 513 Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review. *J Am*
20 514 *Coll Cardiol*. 2023;82:1264–79. doi: 10.1016/j.jacc.2023.06.044
21
22
23 515 39 Sedlak T, Herscovici R, Cook-Wiens G, *et al*. Predicted Versus Observed Major Adverse Cardiac
24 516 Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease:
25 517 A Report From WISE (Women’s Ischemia Syndrome Evaluation). *J Am Heart Assoc*.
26 518 2020;9:e013234. doi: 10.1161/JAHA.119.013234
27
28
29 519 40 Moreau P, d’Uscio LV, Lüscher TF. Structure and reactivity of small arteries in aging. *Cardiovasc*
30 520 *Res*. 1998;37:247–53. doi: 10.1016/s0008-6363(97)00225-3
31
32
33 521 41 Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and
34 522 treatment. *Coron Artery Dis*. 2018;29:161–7. doi: 10.1097/MCA.0000000000000598
35
36
37 523 42 Gan T, Hu J, Liu W, *et al*. Causal Association Between Anemia and Cardiovascular Disease: A 2-
38 524 Sample Bidirectional Mendelian Randomization Study. *J Am Heart Assoc*. 2023;12:e029689. doi:
39 525 10.1161/JAHA.123.029689
40
41
42 526 43 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated
43 527 with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.
44 528 *Circulation*. 2003;107:223–5. doi: 10.1161/01.cir.0000052622.51963.fc
45
46
47 529 44 Herzog CA, Asinger RW, Berger AK, *et al*. Cardiovascular disease in chronic kidney disease. A
48 530 clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*.
49 531 2011;80:572–86. doi: 10.1038/ki.2011.223
50
51
52 532 45 Liu F, Ma G, Tong C, *et al*. Elevated blood urea nitrogen-to-creatinine ratio increased the risk of
53 533 Coronary Artery Disease in patients living with type 2 diabetes mellitus. *BMC Endocr Disord*.
54 534 2022;22:50. doi: 10.1186/s12902-022-00954-3
55
56
57 535 46 Kirtane AJ, Leder DM, Waikar SS, *et al*. Serum blood urea nitrogen as an independent marker of
58 536 subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Superior (ABES)

- glomerular filtration rates. *J Am Coll Cardiol*. 2005;45:1781–6. doi: 10.1016/j.jacc.2005.02.068
- 47 He X, Liu C, Chen Y, *et al*. Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. *Can J Cardiol*. 2018;34:999–1003. doi: 10.1016/j.cjca.2018.03.013
- 48 Wannamethee SG, Shaper AG, Lennon L, *et al*. Mild hyponatremia, hypernatremia and incident cardiovascular disease and mortality in older men: A population-based cohort study. *Nutr Metab Cardiovasc Dis NMCD*. 2016;26:12–9. doi: 10.1016/j.numecd.2015.07.008
- 49 Ahn SY, Park YS, Lee SW, *et al*. Association Between Small Decrease in Serum Sodium Concentration within the Normal Range and All-Cause and Cardiovascular Mortality in Elderly Adults over 5 Years. *J Am Geriatr Soc*. 2016;64:510–7. doi: 10.1111/jgs.13937
- 50 Sajadieh A, Binici Z, Mouridsen MR, *et al*. Mild hyponatremia carries a poor prognosis in community subjects. *Am J Med*. 2009;122:679–86. doi: 10.1016/j.amjmed.2008.11.033
- 51 Doust JA, Pietrzak E, Dobson A, *et al*. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *BMJ*. 2005;330:625. doi: 10.1136/bmj.330.7492.625
- 52 McKie PM, Rodeheffer RJ, Cataliotti A, *et al*. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertens Dallas Tex* 1979. 2006;47:874–80. doi: 10.1161/01.HYP.0000216794.24161.8c
- 53 Wang TJ, Larson MG, Levy D, *et al*. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med*. 2004;350:655–63. doi: 10.1056/NEJMoa031994
- 54 Rosenberg J, Schou M, Gustafsson F, *et al*. Prognostic threshold levels of NT-proBNP testing in primary care. *Eur Heart J*. 2009;30:66–73. doi: 10.1093/eurheartj/ehn525
- 55 Kistorp C, Raymond I, Pedersen F, *et al*. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA*. 2005;293:1609–16. doi: 10.1001/jama.293.13.1609
- 56 Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms, Evaluation, and Clinical Significance. *JACC Cardiovasc Imaging*. 2017;10:65–77. doi: 10.1016/j.jcmg.2016.11.003
- 57 Krahn AD, Manfreda J, Tate RB, *et al*. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med*. 1995;98:476–84. doi: 10.1016/S0002-9343(99)80348-9
- 58 Marsan NA, Maffessanti F, Tamborini G, *et al*. Left atrial reverse remodeling and functional improvement after mitral valve repair in degenerative mitral regurgitation: a real-time 3-

1
2
3 571 dimensional echocardiography study. *Am Heart J.* 2011;161:314–21. doi:
4 572 10.1016/j.ahj.2010.10.029
5
6
7 573 59 Lloyd-Jones DM, Wang TJ, Leip EP, *et al.* Lifetime risk for development of atrial fibrillation: the
8 574 Framingham Heart Study. *Circulation.* 2004;110:1042–6. doi:
9 575 10.1161/01.CIR.0000140263.20897.42
10
11
12 576 60 Bozkurt B, Coats AJS, Tsutsui H, *et al.* Universal definition and classification of heart failure: a
13 577 report of the Heart Failure Society of America, Heart Failure Association of the European Society
14 578 of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition
15 579 of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of
16 580 India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur*
17 581 *J Heart Fail.* 2021;23:352–80. doi: 10.1002/ejhf.2115
18
19
20
21 582 61 Heidenreich PA, Bozkurt B, Aguilar D, *et al.* 2022 AHA/ACC/HFSA Guideline for the
22 583 Management of Heart Failure: A Report of the American College of Cardiology/American Heart
23 584 Association Joint Committee on Clinical Practice Guidelines. *Circulation.* 2022;145:e895–1032.
24 585 doi: 10.1161/CIR.0000000000001063
25
26
27
28 586
29
30
31 587

32
33
34 588 **Figure and table**
35
36
37 589
38
39
40 590

41
42 591 **Figure 1. Flowchart of study participation.** CAD, coronary artery disease.
43
44
45 592

46
47
48 593 **Figure 2. Variable Selection Based on LASSO Regression.** (A) Variation Characteristics of Variable
49
50
51 594 Coefficients; (B) Selection Process of Optimal λ Value in LASSO Regression Model Using Cross-
52
53 595 Validation.
54
55
56 596

57
58
59 597 **Figure 3. Nomogram for predicting the probability of 1-, 2-, and 3-year event-free survival of**
60
ANOCA patients as assessed by coronary angiography. ALT, alanine transaminase; AST, aspartate
transaminase; LVEF, left ventricular ejection fraction.

Figure 4. Receiver operating characteristic curve for the 1-, 2-, and 3-year primary endpoints of the nomogram in the training set (A) and validation set (B). AUC, area under receiver operating characteristic curve.

Figure 5. Calibration plot of predicted 1-, 2-, and 3-year event-free survival based on the nomogram in the training set and validation set. (A–C) Training set; (D–F) Validation set.

Figure 6. Decision curve analysis of the nomogram in the training cohort (A) and validation cohort (B). The x-axis represents the threshold probability, and the y-axis measures the net benefit. The left-slanting straight line shows the net benefit of treating all patients. The bottom horizontal gray line represents the net benefit of not treating any patients. The curve in the middle represents the nomogram.

Figure 7. Kaplan-Meier curves for primary endpoint event-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Consecutive patients underwent coronary angiography
(n =17816)

Patients excluded:

Obstructive CAD (n =9883)

Prior CAD (n =1816)

Missing baseline or follow-up data (n =131)

Severe diseases (n = 52)

Accessed for enrolled (n =5934)

Randomly assigned (0.75:0.25)

Train set (n=4452)

Validation set (n=1482)

LASSO and COX regression


Internal validation

Nomogram


Discrimination and
calibration


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A




B












1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A





B






Downloaded from <http://bmjopen.bmj.com/> on June 8, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).
All rights reserved. No reuse allowed without permission.
by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Number at risk

Low	3946	2875	1906	927	66
High	506	353	189	71	10

Time (Days)



Number at risk

Low	1336	993	648	325	34
High	146	92	51	20	0

Time (Days)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplement

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.


Supplementary Table 1. Clinical data of the total population, training set and validation set.

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
Female, n (%)	3462 (58.3%)	2609 (58.6%)	853 (57.6%)	0.499
Age, years	43.6 (10.8)	43.7 (10.9)	43.5 (10.6)	0.563
Smoking, n (%)	1509 (25.4%)	1126 (25.3%)	383 (25.8%)	0.698
Drinking, n (%)	1883 (31.7%)	1415 (31.8%)	468 (31.6%)	0.909
Hypertension, n (%)	3698 (62.3%)	2802 (62.9%)	896 (60.5%)	0.094
Diabetes mellitus, n (%)	1123 (18.9%)	846 (19.0%)	277 (18.7%)	0.820
Diabetic complications, n (%)	19 (0.32%)	13 (0.29%)	6 (0.40%)	0.595
Dyslipidemia, n (%)	582 (9.81%)	423 (9.50%)	159 (10.7%)	0.185
CKD, n (%)	202 (3.40%)	151 (3.39%)	51 (3.44%)	0.993
SBP, mmHg	136 (19.8)	136 (19.9)	136 (19.7)	0.340
DBP, mmHg	81.9 (12.3)	81.9 (12.4)	81.8 (11.9)	0.757
Heart rate, beats/min	73.8 (15.2)	73.8 (13.9)	73.9 (18.5)	0.798
WBC, 10 ⁹ /L	6.67 (2.03)	6.68 (2.01)	6.67 (2.11)	0.969
Hemoglobin, g/L	136 (16.6)	136 (16.6)	136 (16.4)	0.881
Urea, mmol/L	6.09 (2.68)	6.09 (2.72)	6.08 (2.57)	0.831
Serum creatinine, µmol/L	65.9 [55.7; 79.8]	66.2 [55.7; 79.7]	65.4 [55.5; 80.0]	0.748
Uric acid, µmol/L	335 (100)	335 (101)	335 (99.0)	0.889
Serum sodium, mmol/L	142 (3.51)	142 (3.32)	142 (4.01)	0.829
Serum potassium, mmol/L	4.12 (0.56)	4.12 (0.47)	4.13 (0.76)	0.649
Serum chloride, mmol/L	106 (3.37)	106 (3.42)	106 (3.21)	0.515
Anion gap, mmol/L	14.0 (2.40)	13.9 (2.40)	14.0 (2.42)	0.844

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
Total protein, g/L	68.2 (6.41)	68.2 (6.37)	68.2 (6.54)	0.968
Albumin, g/L	42.4 (3.88)	42.4 (3.87)	42.3 (3.91)	0.406
Globulin, g/L	25.9 (4.19)	25.8 (4.16)	25.9 (4.30)	0.353
ALT, U/L	17.7 [13.0; 24.7]	17.8 [13.1; 24.8]	17.6 [12.6; 24.5]	0.169
AST, U/L	17.7 [14.6; 21.6]	17.8 [14.6; 21.6]	17.5 [14.6; 21.5]	0.341
ALT/AST ratio	1.06 (0.41)	1.05 (0.41)	1.07 (0.42)	0.157
Total bilirubin, µmol/L	13.6 (6.67)	13.6 (6.81)	13.4 (6.23)	0.257
Indirect Bilirubin, µmol/L	9.63 (4.69)	9.67 (4.75)	9.51 (4.53)	0.242
Direct Bilirubin, µmol/L	3.40 [2.30; 4.60]	3.40 [2.30; 4.60]	3.40 [2.40; 4.60]	0.611
Alkaline phosphatase, U/L	76.5 (23.6)	76.5 (23.6)	76.6 (23.7)	0.820
Total cholesterol, mmol/L	4.75 (1.12)	4.75 (1.13)	4.74 (1.08)	0.919
Triglycerides, mmol/L	1.63 (1.11)	1.62 (1.11)	1.65 (1.10)	0.485
HDL-C, mmol/L	1.22 (0.31)	1.22 (0.32)	1.20 (0.30)	0.083
LDL-C, mmol/L	2.97 (0.88)	2.97 (0.88)	2.98 (0.87)	0.498
VLDL-C, mmol/L	0.56 (0.37)	0.56 (0.39)	0.56 (0.30)	0.627
Troponin I, ng/ml	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.536
NT-proBNP, ng/L	83.7 [35.1; 266]	83.0 [34.3; 265]	86.7 [38.0; 269]	0.415
CKMB, U/L	12.1 [9.30; 14.7]	12.0 [9.24; 14.7]	12.3 [9.30; 14.7]	0.529
D-Dimer, µg/L	276 [2.34; 434]	274 [1.78; 427]	282 [4.65; 457]	0.110
Glucose, mmol/L	6.81 (2.48)	6.82 (2.45)	6.78 (2.56)	0.579
Left atrial diameter, mm	38.7 (5.24)	38.7 (5.28)	38.6 (5.11)	0.331

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
LVEDD, mm	47.4 (4.46)	47.4 (4.51)	47.3 (4.28)	0.373
LVESD, mm	26.9 (5.62)	26.9 (5.65)	27.0 (5.52)	0.737
RVEDD, mm	20.8 (3.37)	20.7 (3.61)	20.8 (2.53)	0.623
LVEF, %	61.7 (6.75)	61.7 (6.77)	61.6 (6.70)	0.486
Event-free survival time, days	635 (403)	633 (402)	641 (406)	0.512
Death, n (%)	106 (1.79%)	78 (1.75%)	28 (1.89%)	0.816
MI endpoint, n (%)	33 (0.56%)	21 (0.47%)	12 (0.81%)	0.189
Stroke endpoint, n (%)	11 (0.19%)	6 (0.13%)	5 (0.34%)	0.156
MACE, n (%)	82 (1.38%)	64 (1.44%)	18 (1.21%)	0.611
Primary endpoint, n (%)	145 (2.44%)	105 (2.36%)	40 (2.70%)	0.523

CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; CKMB, creatine kinase-MB; LVEDD, left ventricular-end-diastolic diameter; LVESD, left ventricular-end-systolic diameter; RVEDD, right ventricular-end-diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MACE, major adverse cardiovascular events.




Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population


Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Supérieur (ABES).

A



B



Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

BMJ Open

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-092614.R2
Article Type:	Original research
Date Submitted by the Author:	23-Apr-2025
Complete List of Authors:	Zhu, Lei; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Xue, Zheng-Kai; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Wu, Xue; University of California San Francisco, Institute for Global Health Sciences Zhang, JingKun; University of California San Francisco, Cardiovascular Research Institute Hu, Su-Tao; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Zhang, Yu-Kun; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Gu, Tian-Shu; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Liu, Tong; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Rha, Seung-Woon; Korea University Guro Hospital, Cardiovascular Center Chen, Kang-Yin; The Second Hospital of Tianjin Medical University, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Angina Pectoris, Coronary heart disease < CARDIOLOGY, Prognosis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

1

2

3

Development and validation of a risk prediction model for adverse outcomes in patients with suspected coronary artery disease and no significant stenosis on angiography: a retrospective cohort study

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Authors: Lei Zhu¹, Zheng-Kai Xue¹, Xue Wu², Jing-Kun Zhang³, Su-Tao Hu¹, Yu-Kun Zhang¹, Tian-Shu Gu¹, Tong Liu¹, Seung-Woon Rha⁴, Kang-Yin Chen^{1*}

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Affiliations: ¹ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, China

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

² Institute for Global Health Sciences, University of California, San Francisco, CA, USA

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

³ Cardiovascular Research Institute, University of California San Francisco, CA, USA

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

⁴ Cardiovascular Center, Korea University Guro Hospital, Seoul, Republic of Korea.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

*Corresponding author: Kang-Yin Chen, MD, PhD, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Hexi District, Tianjin 300211, China (chenkangyin@vip.126.com)

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Word count: 3081

Abstract

Objectives

To develop and validate a risk prediction model for adverse outcomes in patients with angina with nonobstructive coronary arteries (ANOCA) confirmed by invasive coronary angiography.

Design

Retrospective cohort study.

Setting

A tertiary cardiovascular care center in China.

Participants

From 17,816 consecutive patients undergoing coronary angiography for suspected coronary artery disease, 5,934 met ANOCA criteria after rigorous exclusion: (1) significant stenosis ($\geq 50\%$ luminal narrowing), (2) established coronary artery disease history, (3) incomplete baseline/follow-up data, (4) non-cardiovascular life-limiting conditions.

primary and secondary outcome measures

The primary outcome was a composite of all-cause death, nonfatal myocardial infarction (MI), stroke, and repeat percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG). The secondary outcome was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

The derivation cohort (n=4,452) and validation cohort (n=1,482) demonstrated comparable baseline characteristics. The nomogram incorporated eight prognosticators: age, hemoglobin, serum urea, serum sodium, alanine aminotransferase (ALT) / aspartate aminotransferase (AST) ratio, N-terminal pro-B-type natriuretic peptide (NT-proBNP), left atrial diameter, and left ventricular ejection fraction (LVEF). The prediction model showed robust discrimination for primary endpoint, achieving area under the curve (AUC) values of 0.82 (1-year), 0.90 (2-year), and 0.89 (3-year) in the derivation cohort, with corresponding validation cohort AUCs of 0.75, 0.77, and 0.78. Calibration plots revealed close alignment between predicted and actual event-free survival probabilities in both cohorts. Risk stratification identified two distinct prognostic groups with significant survival differences (log-rank $p < 0.0001$).

Conclusions

This predictive model integrates routinely available clinical parameters to accurately stratify mortality and cardiovascular risk in ANOCA patients, providing a potential valuable decision-support tool for personalized therapeutic strategies.

Strengths and limitations of this study

- This study utilized a large sample size (n=5934) with rigorous internal validation through training and testing cohorts.
- Leveraged LASSO-penalized Cox regression with 10-fold cross-validation to optimize model

generalizability.

- The nomogram integrates routinely available clinical variables, enhancing clinical applicability.
- Limitations include the retrospective design, which may introduce selection bias.
- Data were derived from a single center, potentially limiting generalizability.

Key word

Angina, coronary artery disease, MINOCA, prognosis, nomogram.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Backgrounds

Chest pain is a common symptom among patients seeking medical services, often raising concerns about potentially life-threatening conditions such as coronary artery disease (CAD) [1,2]. Timely and accurate diagnostic assessments, including electrocardiography, coronary computed tomography angiography (CCTA), and coronary angiography (CAG), are frequently recommended for individuals presenting with chest pain to rule out severe conditions such as myocardial infarction (MI) [3,4]. However, in the cohort of patients undergoing diagnostic workup, approximately half exhibit nonobstructive coronary arteries (stenosis less than 50%)[5,6], a condition known as angina with nonobstructive coronary arteries (ANOCA) [7].

ANOCA patients often seek medical care due to symptoms and undergo repetitive invasive examinations, leading to significant healthcare resource utilization and imposing individual burdens and additional risks [8–10]. In a randomized controlled trial involving over 10,000 patients suspected of CAD with intermediate pretest likelihood, only approximately 12% of them yielded a positive result in the final coronary artery functional tests [11]. Patients with a low pretest probability exhibit an exceedingly low positivity rate in diagnostic workup and experience fewer adverse outcomes [12]. Therefore, clinical guidelines recommend delaying diagnostic testing for patients at low risk for CAD[13,14]. However, patients without obstructive coronary arteries confirmed by CAG or CCTA have been observed to experience more adverse outcomes compared to the general population[15–17].

Identifying high-risk individuals in ANOCA patients remains a challenge.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

There is limited research on predicting adverse outcomes in ANOCA patients confirmed through CAG or CCTA. Some studies have validated the utility of specific pretest indicators, such as age, sex, and traditional cardiovascular disease risk factors (e.g., hypertension), to identify low-risk ANOCA patients [18]. However, several investigations have shown that specific blood biomarkers, including high-sensitivity troponin and lower high-density lipoprotein cholesterol (HDL-C) levels, operate as independent predictive factors for poor prognosis in ANOCA patients, adding prognostic value [19]. To date, comprehensive studies that screen noninvasive indicators and develop a prognostic model are lacking, and most previous studies are reliant on data derived from the Women's Ischemia Syndrome Evaluation (WISE) study [19–21], which exclusively includes female participants. One study also used WISE data to validate the effectiveness of some risk scores originally designed for other populations, such as the Atherosclerotic Cardiovascular Disease (ASCVD) score, in predicting adverse outcomes in ANOCA patients, but the results showed suboptimal performance [22]. Therefore, it is necessary to develop a predictive model based on non-invasive indicators to forecast adverse outcomes in ANOCA patients of both sexes. This study aims to bridge this gap to optimize clinical decision-making and patient management.

Method

Study Population

This is a retrospective cohort study that consecutively enrolled patients who presented with suspected

1
2
3
4 105 symptoms of CAD and underwent coronary angiography at the department of cardiology or emergency
5
6
7 106 department of the Second Hospital of Tianjin Medical University between January 2019 and June 2023.
8
9
10 107 The Second Hospital of Tianjin Medical University is a cardiac center serving the northern Chinese
11
12 108 city of Tianjin and its surrounding regions. This study adheres to the principles outlined in the TRIPOD
13
14
15 109 statement [23].
16
17
18 110

19
20 111 ANOCA patients were defined as angina with nonobstructive epicardial coronary arteries (stenosis
21
22
23 112 <50%), adhering to current expert consensus[7]. Patients meeting the following criteria were excluded
24
25
26 113 from the study: (1) patients with acute coronary syndrome or obstructive coronary arteries (defined as
27
28
29 114 a luminal stenosis of $\geq 50\%$ in a major epicardial coronary artery[7,24]); (2) patients with a prior
30
31 115 diagnosis of CAD, history of percutaneous coronary intervention (PCI), or coronary artery bypass
32
33
34 116 grafting (CABG); (3) individuals with severe liver or kidney dysfunction, malignancies, or other non-
35
36
37 117 cardiovascular conditions significantly affecting life expectancy; (4) those with substantial missing
38
39
40 118 baseline data; and (5) patients lost to follow-up. This study received approval from the Ethics
41
42 119 Committee of the Second Hospital of Tianjin Medical University, with a waiver for written informed
43
44
45 120 consent granted for the retrospective use of fully anonymized clinical data (No. KY2025K008).
46
47
48 121

49
50
51 122 **Clinical Data Collection**
52
53
54

55 123 Patient data were retrospectively obtained from electronic medical records, including demographic
56
57
58 124 information, medical history, vital sign data, laboratory parameters, echocardiographic data, coronary
59
60

angiography findings and other relevant details.

Follow-Up and Endpoints

A dedicated follow-up team conducted systematic post-discharge surveillance through a standardized protocol, with scheduled assessments at 30 days, 3 months, 6 months, and annually thereafter. Data collection employed a multimodal approach: (1) comprehensive electronic health record review, (2) cross-referencing with regional death registries, (3) and telephone or email interviews. The observational window for this analysis was finalized on August 1, 2023. Two board-certified cardiologists (L.Z. and Z.K.X., each with >5 years clinical experience) independently evaluated all events using standardized diagnostic criteria[25,26]. For discrepancies in event classification, an adjudication committee comprising two senior interventional cardiologists (T.L. and K.Y.C., both with >20 years catheterization laboratory experience) conducted final arbitration through consensus review.

The primary endpoint was a composite of all-cause death, nonfatal MI, stroke, and repeat PCI or CABG during follow-up. The secondary endpoint was major adverse cardiovascular events (MACE), defined as cardiac-related death, nonfatal MI, nonfatal stroke, repeat PCI, and CABG during follow-up. The composite endpoint was selected based on its established utility in prognostic studies of ANOCA [22,27–29].

1
2
3
4 145
5
6
7
8 146
9
10
11 147
12
13 148
14
15
16 149
17
18
19 150
20
21
22 151
23
24 152
25
26
27 153
28
29
30 154
31
32 155
33
34
35 156
36
37
38 157
39
40
41 158
42
43 159
44
45
46 160
47
48
49 161
50
51
52 162
53
54 163
55
56
57 164
58
59
60 165

Statistical Analysis

For the small amount of missing data in smoking and alcohol consumption history, multiple imputation was performed using the MICE package (Multiple Imputation by Chained Equations package). To establish a reliable model, the entire study cohort was randomly stratified into two subsets, a training set and a validation set, with a ratio of 0.75 to 0.25, respectively. The training set was used to generate the predictive model, while the validation set was utilized for model internal validation.

Categorical variables were described as frequencies and percentages, with group differences assessed using the chi-square test or Fisher's exact test as applicable. Continuous variables were expressed as either the mean ± standard deviation (SD) or median [interquartile range, IQR], and group comparisons were conducted using the t test or Kruskal–Wallis test as appropriate. Variables with variance inflation factor (VIF) ≥5 were excluded prior to LASSO regression to mitigate multicollinearity. The variables selected through LASSO regression were incorporated into the Cox proportional hazards regression model, and a nomogram was generated based on the Cox regression analysis model. The discriminative ability of the predictive model was evaluated using area under the curve (AUC). The model's calibration was assessed through the calibration curve. Additionally, decision curve analysis was employed to evaluate the clinical utility of the nomogram.

The total score for each patient was calculated based on the nomogram, and the study population was stratified into high-risk and low-risk groups according to the score corresponding to the 3-year 95% event-free survival probability. Event-free survival for the high- and low-risk groups in the training

and validation sets was estimated by Kaplan–Meier method and compared with the log-rank test. All statistical analyses were performed with R software version 4.3.1 (R Foundation for Statistical Computing). All statistical tests were two- tailed, with a significance level set at $P < 0.05$.

Patient and public involvement

None.

Result

Study Population and Patient Characteristics

Out of a consecutive cohort of 17,816 patients who underwent coronary angiography for suspected coronary artery disease, 9,883 individuals with significant coronary artery stenosis and 1,816 patients with a documented history of coronary heart disease were excluded. An additional 131 individuals were excluded due to missing baseline or follow-up data, and 52 patients with severe conditions such as malignant tumors were also excluded. of the final analysis included 5,934 patients with negative coronary angiography results (**Figure 1**).

The mean age of the overall cohort was 43.6 ± 10.8 years, with 58.3% being female, and the median follow-up time was 631 [270, 972] days. Detailed baseline data are provided in **Supplementary Table 1**. During the follow-up period, 145 (2.44%) patients had primary endpoint events, 82 (1.38%) had MACE, 106 (1.79%) had all-cause death, 33 (0.56%) had MI, and 11 (0.19%) had a stroke. The

1
2
3
4 186 Kaplan-Meier method was employed to estimate the survival without various adverse events for the
5
6
7 187 total study population (**Supplementary Figure 1**).
8
9
10 188

11
12
13 189 **Nomogram built based on LASSO-COX regression**
14
15
16

17 190 The entire cohort was randomly divided into a training cohort consisting of 4,452 patients and a
18
19
20 191 validation cohort comprising 1,482 patients. There were no statistically significant differences in the
21
22
23 192 collected variables between these two groups (**Supplementary Table 1**). LASSO regression was
24
25 193 employed to select variables with the strongest correlation to the primary endpoint. As the
26
27
28 194 regularization parameter (λ) increased, certain coefficients were reduced to zero, effectively
29
30
31 195 eliminating those variables from the model (**Figure 2A**). We used a tenfold cross-validation approach
32
33
34 196 to identify the optimal model. Due to the relatively limited number of cases undergoing primary
35
36 197 endpoint events in the validation cohort (145), we employed the one standard error (1-se) rule, resulting
37
38
39 198 in eight selected variables (**Figure 2B**). These variables were incorporated into a Cox proportional
40
41
42 199 hazards regression model, with results presented in **Table 1**. All models satisfied proportional hazards
43
44
45 200 assumptions (global test $p=0.057$). A nomogram was developed based on the Cox regression model,
46
47 201 with the regression coefficients of these factors amalgamated into a scoring system, ranging from 0 to
48
49
50 202 100(**Figure 3**). For example, an 81-year-old male patient with a hemoglobin level of 92 g/L, serum
51
52
53 203 urea of 14.1 mmol/L, serum sodium of 145.6 mmol/L, an ALT/AST ratio of 1.68, NT-proBNP at 272
54
55 204 ng/L, left atrial diameter of 38.83 millimeters, and an LVEF of 62% received a total score of 115. The
56
57
58 205 1-year, 2-year and 3-year event-free survival rates were 99.5%, 96.2% and 89.0%, respectively.
59
60

Table 1. Prediction of event-free survival probability using the Cox proportional hazards regression model based on LASSO regression.

Variable	coefficients	z score	HR	95%CI	p value
Age	0.043	4.167	1.044	0.023, 0.063	<0.001
Hemoglobin	-0.015	-2.871	0.985	-0.026, -0.005	0.004
Urea	0.074	3.947	1.077	0.037, 0.111	<0.001
Serum sodium	-0.074	-5.694	0.929	-0.1, -0.049	<0.001
ALT/AST ratio	0.444	2.439	1.559	0.087, 0.8	0.015
NT-proBNP	0	2.094	1	0, 0	0.036
Left atrial diameter	0.076	5.959	1.079	0.051, 0.8	<0.001
LVEF	-0.022	-2.289	0.979	-0.04, -0.003	0.022

HR, hazard ratio; CI, confidence interval; ALT, alanine transaminase; AST, aspartate transaminase;

NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEF, left ventricular ejection fraction.

Discrimination and calibration of the nomogram

The discriminative ability of the model was assessed by plotting receiver operating characteristic curves. In the training set, the AUC for 1-, 2-, and 3-year predictions was 0.82, 0.90, and 0.89, respectively. In the validation set, the corresponding AUC for 1-, 2-, and 3-year predictions were 0.75, 0.77, and 0.78, respectively (**figure 4**).

Figure 5 illustrates calibration plots for the models predicting 1-, 2-, and 3-year survival in both the training and validation datasets. In well-calibrated models, the points closely align with the ideal 45-degree line, indicating that predicted survival closely matches observed survival and demonstrating

1
2
3
4 221 good model calibration.
5
6
7 222

10
11 223 **Decision Curve**
12
13

14
15 224 Decision curve analysis was employed to evaluate the potential improvement in clinical outcomes
16
17 225 through nomogram-assisted decision-making for patients. As illustrated in **Figure 6**, the results reveal
18
19
20 226 that across a broad spectrum of threshold probabilities in both the training and testing cohorts, utilizing
21
22
23 227 the nomogram for predicting the 2-year or 3-year event-free survival probability offers a more
24
25 228 significant net benefit when compared to strategies of 'treat all' or 'treat none.' These findings
26
27
28 229 underscore the clinical utility of the nomogram.
29
30
31 230

32
33
34
35 231 **Risk stratification**
36
37

38
39 232 Considering that the study population consists of low-risk patients with non-obstructive coronary
40
41 233 artery stenosis, the threshold for further risk stratification was set at a higher event-free survival
42
43
44 234 probability, specifically a score of 104 points corresponding to the 95% 3-year event-free survival
45
46
47 235 probability as determined by the nomogram. Individuals scoring below this threshold were categorized
48
49
50 236 as low-risk, while those scoring equal to or above it were classified as high-risk. Kaplan-Meier curves
51
52 237 depicting event-free survival were created for the two risk groups in the training and validation sets
53
54
55 238 (**Figure 7**). Furthermore, MACE-event free survival of these groups is shown in **Supplementary**
56
57
58 239 **Figure 2**. These results consistently demonstrated the model's efficacy in patient risk stratification.
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

Discussion

This study focused on patients initially suspected of having CAD but who were found to have nonobstructive coronary arteries following coronary angiography. A wide range of variables, including demographic information, vital signs, laboratory parameters, and echocardiographic measurements, were meticulously examined. Ultimately, 8 key variables, namely age, hemoglobin levels, serum urea, serum sodium levels, ALT/AST ratio, NT-proBNP levels, left atrial diameter, and LVEF, were identified. The study successfully developed a nomogram to predict the probability of event-free survival for these patients, demonstrating excellent discriminatory and calibration abilities in both the training and validation sets. The utilization of this predictive model in clinical practice empowers healthcare providers to conduct more precise risk stratification, particularly for individuals initially classified as low-risk, thereby improving diagnostic, management, and treatment strategies and ultimately enhancing patient outcomes.

In clinical practice, a substantial number of patients with potential cardiac issues, such as chest pain, actively seek medical attention in both outpatient and emergency department settings. In the United Kingdom, for instance, approximately 1-2% of adults consult primary care facilities when experiencing chest pain for the first time [15]. Similarly, millions of individuals in the United States undergo stress tests in outpatient clinics each year for undiagnosed heart conditions [30]. However, research has

1
2
3
4 260 consistently shown that following diagnostic assessments like coronary angiography, approximately
5
6
7 261 50% of patients do not exhibit obstructive coronary artery stenosis [5,16,24,31]. Traditionally, such
8
9
10 262 patients were often considered to have a favorable prognosis and no significant cardiac conditions ,
11
12 263 potentially resulting in the omission of further diagnostic measures and therapeutic interventions [32–
13
14
15 264 34]. However, recent research has indicated that these patients face a significantly elevated risk of
16
17
18 265 adverse outcomes compared to the general population. The WISE study revealed that at over a 10-year
19
20 266 follow-up, patients without obstructive coronary stenosis on coronary angiography had rates of
21
22
23 267 cardiovascular death and MI of 6.7% and 12.8%, respectively, underscoring the heightened risk among
24
25
26 268 female ANOCA patients [21,35,36]. Other studies have also demonstrated that ANOCA patients,
27
28
29 269 regardless of their gender, face an increased risk of experiencing CAD-related outcomes compared to
30
31 270 the general population[16,31,37].
32
33
34 271
35
36
37 272 Our findings from this study indicate that ANOCA patients tend to be younger, with an average age of
38
39 273 43.6 years, and a higher proportion of them are female (58.3%) [7]. During a median follow-up period
40
41
42 274 of 2 years, the rates of all-cause death, MI, and stroke were 1.79%, 0.56%, and 0.19%, respectively.
43
44
45 275 These findings align with a previous study reporting 1-year MI rates ranging from 0.11% to 0.59% and
46
47
48 276 1-year mortality rates ranging from 1.38% to 2.3% [31]. Our research further supports the
49
50 277 characterization of ANOCA patients and provides additional evidence of their elevated risk for adverse
51
52
53 278 outcomes across diverse populations.
54
55
56 279
57
58 280 While clinical guidelines suggest risk stratification of chest pain patients and deferring testing for those
59
60

with a low likelihood of CAD, this strategy may inadvertently exclude high-risk ANOCA patients who require further assessment and appropriate therapeutic interventions [13,14]. As highlighted in a recent review, a significant proportion of ANOCA patients (ranging from 75% to 90%) exhibit various underlying causes, such as coronary microvascular dysfunction, microvascular spasm, endothelial dysfunction, epicardial coronary spasm, and/or myocardial bridging [7,38], emphasizing the critical importance of identifying high-risk ANOCA patients to optimize their further management.

Current research on factors related to adverse outcomes in the ANOCA population is limited. One study attempted to develop a risk tool for chest pain patients with normal coronary arteries to predict favorable outcomes. This tool comprised 10 variables, including age, gender, and the presence of conditions like hypertension, diabetes, or dyslipidemia. However, it is important to note that this study solely relied solely on pretest clinical data and accessed coronary arteries through CCTA [18]. In contrast, our predictive model incorporated pre-test indicators, including demographic variables and medical history, with age being one of the key factors. Age is a variable included in many traditional CAD prediction models because it is easily obtainable and reflects the aging of the entire cardiovascular system, including increased arterial stiffness and decreased vascular endothelial function [39,40].

Previous studies have also indicated that several blood biomarkers are associated with unfavorable outcomes in ANOCA patients, including lower levels of HDL-C, elevated levels of soluble urokinase-type plasminogen activator receptor, and high-sensitivity troponin [19,20]. However, none of these

1
2
3
4 302 studies conducted comprehensive screening of clinical variables or developed a predictive model.
5
6
7 303 After a thorough screening of blood biomarkers, our predictive model incorporated hemoglobin, serum
8
9
10 304 urea, serum sodium and NT-proBNP, which are rarely reported to be associated with adverse outcomes
11
12 305 in ANOCA patients. Anemia, for example, is a common pathological condition involved in the
13
14
15 306 occurrence and development of CAD and heart failure through various mechanisms [41]. It
16
17
18 307 significantly increases the risk of developing CAD and heart failure and is associated with adverse
19
20 308 outcomes in these patients [42,43]. Serum urea reflects renal function, which is a crucial factor
21
22
23 309 influencing the cardiovascular system [44]. Previous research has shown that an elevated serum urea
24
25
26 310 levels increase the risk of CAD and serve as a predictive factors for adverse outcomes in CAD and
27
28
29 311 heart failure patients [45,46]. The role of serum sodium in cardiovascular disease is still not fully
30
31 312 understood, but several studies have indicated that even mild reductions in serum sodium, even within
32
33
34 313 the normal range, are associated with higher all-cause mortality and cardiovascular mortality in elderly
35
36
37 314 individuals or the general population [47–50]. The underlying mechanisms behind this association
38
39 315 require further research. NT-proBNP is a widely recognized marker for heart failure and exhibits
40
41
42 316 strong predictive capabilities for the prognosis of heart failure patients [51]. Previous studies have also
43
44
45 317 demonstrated its ability to predict cardiovascular events and mortality even in community-dwelling or
46
47
48 318 elderly populations without heart failure [52–55].
49
50 319
51
52
53 320 Our predictive model also considered echocardiographic parameters. Echocardiography is a
54
55
56 321 noninvasive, easily performed, and cost-effective imaging technique that provides comprehensive
57
58 322 insights into cardiac structure and function. In our model, left atrial diameter and LVEF were included.
59
60

Left atrial enlargement is closely associated with conditions like atrial fibrillation and heart failure, and factors such as hypertension and mitral valve diseases can also lead to left atrial enlargement. It is commonly regarded as a biomarker for adverse cardiovascular outcomes [56–59]. The LVEF serves as one of the diagnostic and classificatory criteria for heart failure, with the latter often signifying the advanced stage of diverse cardiac ailments and indicates an unfavorable prognosis [60,61].

Limitations

This study has several limitations. First, the retrospective design precludes control of treatment strategies and introduces potential selection bias. Second, the study population consisted entirely of individuals from northern China, so caution should be exercised when generalizing the findings of this study to other populations. Third, the inability to subclassify ANOCA patients into those with versus without atherosclerosis represents an important limitation, as pathophysiological differences between these cohorts may contribute to population heterogeneity. However, this aligns with current guideline definitions, and future studies incorporating intracoronary imaging could refine risk stratification. Finally, while the predictive model developed from single-center data has not yet undergone external validation, internal validation confirmed its robust discrimination and calibration, indicating strong performance within the original cohort.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Conclusion

In summary, we conducted a comprehensive evaluation of clinically accessible variables and successfully developed a predictive model for assessing adverse outcomes in angina patients with suspected CAD who do not exhibit obstructive coronary artery stenosis. This nomogram equips clinicians with a valuable tool for risk stratification in ANOCA patients, allowing for optimized management and treatment strategies aimed at improving patient outcomes.

List of abbreviations

- ANOCA, angina with nonobstructive coronary arteries
- MI, myocardial infarction
- PCI, percutaneous coronary intervention
- CABG, coronary-artery bypass grafting
- MACE, major adverse cardiovascular events
- ALT, alanine transaminase
- AST, aspartate transaminase
- NT-proBNP, N-terminal pro-B-type natriuretic peptide
- LVEF, left ventricular ejection fraction
- AUC, area under the curve
- CAD, coronary artery disease

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

CAG, coronary angiography

CCTA, coronary computed tomography angiography

HDL-C, high-density lipoprotein cholesterol

SD, standard deviation

IQR, interquartile range

VIF, variance inflation factor

Funding

This study was supported by the Key Project of Tianjin Natural Science Foundation (Grant Number: 21JCZDJC01080), Academic Backbone of “Clinical Talent Training and Climbing Plan” of Tianjin Medical University.

Data availability statement

The original data supporting the findings of this study can be obtained from the corresponding author upon reasonable request.

Contributors

L.Z. Conceptualization, Investigation, Methodology, Data curation, Software, Formal analysis,

1
2
3
4 381 Visualization, Writing – original draft. Z.K.X. Investigation, Data curation, Formal analysis, Writing
5
6
7 382 – review and editing. X.W. Methodology, Writing – review and editing. J.K.Z. Methodology, Writing
8
9
10 383 – review and editing. S.T.H. Data curation, Writing – review and editing. Y.K.Z. Data curation,
11
12 384 Writing – review and editing. T.S.G. Data curation, Writing – review and editing. T.L. Supervision,
13
14
15 385 Validation, Writing – review and editing. S.W.R. Supervision, Validation, Funding
16
17
18 386 acquisition, Writing – review and editing. K.Y.C. Conceptualization, Funding acquisition,
19
20 387 Project administration, Resources, Supervision, Writing – review and editing. All authors approved
21
22
23 388 the final manuscript. K.Y.C. is responsible for the overall content as guarantor.
24
25
26 389

27
28
29
30 390 **Competing interests**

31
32
33 391 This study received infrastructure support from Tianjin Medical University. The funding organization
34
35
36 392 played no role in study design, data collection, analysis, interpretation, manuscript preparation, or
37
38
39 393 publication decisions. All authors declare no additional competing interests.
40
41
42 394

43
44 395
45
46
47 396
48
49
50 397
51
52
53 398 **References**

54
55
56 399 1 Hoorweg BB, Willemsen RT, Cleef LE, *et al.* Frequency of chest pain in primary care, diagnostic
57 400 tests performed and final diagnoses. *Heart Br Card Soc.* 2017;103:1727–32. doi: 10.1136/heartjnl-
58 401 2016-310905
59
60

- 2 Tsao CW, Aday AW, Almarzooq ZI, *et al.* Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation.* 2022;145:e153–639. doi: 10.1161/CIR.0000000000001052
- 3 Virani SS, Newby LK, Arnold SV, *et al.* 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation.* 2023;148:e9–119. doi: 10.1161/CIR.0000000000001168
- 4 Fihn SD, Gardin JM, Abrams J, *et al.* 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *Circulation.* 2012;126:3097–137. doi: 10.1161/CIR.0b013e3182776f83
- 5 Patel MR, Peterson ED, Dai D, *et al.* Low diagnostic yield of elective coronary angiography. *N Engl J Med.* 2010;362:886–95. doi: 10.1056/NEJMoa0907272
- 6 Rahman H, Corcoran D, Aetesam-Ur-Rahman M, *et al.* Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. *Heart Br Card Soc.* 2019;105:1536–42. doi: 10.1136/heartjnl-2019-315042
- 7 Samuels BA, Shah SM, Widmer RJ, *et al.* Comprehensive Management of ANOCA, Part 1- Definition, Patient Population, and Diagnosis: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2023;82:1245–63. doi: 10.1016/j.jacc.2023.06.043
- 8 Shaw LJ, Merz CNB, Pepine CJ, *et al.* The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. *Circulation.* 2006;114:894–904. doi: 10.1161/CIRCULATIONAHA.105.609990
- 9 Gulati M, Khan N, George M, *et al.* Ischemia with no obstructive coronary artery disease (INOCA): A patient self-report quality of life survey from INOCA international. *Int J Cardiol.* 2023;371:28–39. doi: 10.1016/j.ijcard.2022.09.047
- 10 Takahashi T, Samuels BA, Li W, *et al.* Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols. *J Am Coll Cardiol.* 2022;79:2367–78. doi: 10.1016/j.jacc.2022.03.385
- 11 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med.* 2015;372:1291–300. doi: 10.1056/NEJMoa1415516
- 12 Udelson JE, Kelsey MD, Nanna MG, *et al.* Deferred Testing in Stable Outpatients With Suspected

1
2
3 437 Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized
4 438 Clinical Trial. *JAMA Cardiol.* Published Online First: 23 August 2023. doi:
5 439 10.1001/jamacardio.2023.2614
6
7
8 440 13 Gulati M, Levy PD, Mukherjee D, *et al.* 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR
9 441 Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of
10 442 Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
11 443 *Circulation.* 2021;144:e368–454. doi: 10.1161/CIR.0000000000001029
12
13
14 444 14 Knuuti J, Wijns W, Saraste A, *et al.* 2019 ESC Guidelines for the diagnosis and management of
15 445 chronic coronary syndromes. *Eur Heart J.* 2020;41:407–77. doi: 10.1093/eurheartj/ehz425
16
17
18 446 15 Jordan KP, Timmis A, Croft P, *et al.* Prognosis of undiagnosed chest pain: linked electronic health
19 447 record cohort study. *BMJ.* 2017;357:j1194. doi: 10.1136/bmj.j1194
20
21
22 448 16 Jespersen L, Hvelplund A, Abildstrøm SZ, *et al.* Stable angina pectoris with no obstructive
23 449 coronary artery disease is associated with increased risks of major adverse cardiovascular events.
24 450 *Eur Heart J.* 2012;33:734–44. doi: 10.1093/eurheartj/ehr331
25
26
27 451 17 Gulati M, Cooper-DeHoff RM, McClure C, *et al.* Adverse cardiovascular outcomes in women
28 452 with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome
29 453 Evaluation Study and the St James Women Take Heart Project. *Arch Intern Med.* 2009;169:843–
30 454 50. doi: 10.1001/archinternmed.2009.50
31
32
33 455 18 Fordyce CB, Douglas PS, Roberts RS, *et al.* Identification of Patients With Stable Chest Pain
34 456 Deriving Minimal Value From Noninvasive Testing: The PROMISE Minimal-Risk Tool, A
35 457 Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol.* 2017;2:400–8. doi:
36 458 10.1001/jamacardio.2016.5501
37
38
39 459 19 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble Urokinase-Type Plasminogen Activator
40 460 Receptor and High-Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary
41 461 Artery Disease. *J Am Heart Assoc.* 2020;9:e015515. doi: 10.1161/JAHA.119.015515
42
43
44 462 20 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women
45 463 with non-obstructive CAD on coronary CTA: pooled analysis from PROMISE and SCOT-HEART.
46 464 *Int J Cardiovasc Imaging.* 2022;38:683–93. doi: 10.1007/s10554-021-02429-3
47
48
49 465 21 Sharaf B, Wood T, Shaw L, *et al.* Adverse outcomes among women presenting with signs and
50 466 symptoms of ischemia and no obstructive coronary artery disease: findings from the National Heart,
51 467 Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE)
52 468 angiographic core laboratory. *Am Heart J.* 2013;166:134–41. doi: 10.1016/j.ahj.2013.04.002
53
54
55 469 22 Sedlak T, Herscovici R, Cook-Wiens G, *et al.* Predicted versus observed major adverse cardiac
56 470 event risk in women with evidence of ischemia and no obstructive coronary artery disease: A report
57 471 from WISE (women’s ischemia syndrome evaluation). *J Am Heart Assoc.* 2020;9:e013234. doi:

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

- 10.1161/JAHA.119.013234
- 23 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BMJ*. 2015;350:g7594. doi: 10.1136/bmj.g7594
 - 24 Bairey Merz CN, Pepine CJ, Walsh MN, *et al.* Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. *Circulation*. 2017;135:1075–92. doi: 10.1161/CIRCULATIONAHA.116.024534
 - 25 K T, Js A, As J, *et al.* Fourth universal definition of myocardial infarction (2018). *J Am Coll Cardiol*. 2018;72. doi: 10.1016/j.jacc.2018.08.1038
 - 26 Powers WJ, Rabinstein AA, Ackerson T, *et al.* Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association. *Stroke*. 2019;50:e344–418. doi: 10.1161/STR.0000000000000211
 - 27 Mansour M, Radaideh Q, Alaiwah MN, *et al.* Major adverse cardiac events in symptomatic women with non-obstructive CAD on coronary CTA: Pooled analysis from PROMISE and SCOT-HEART. *Int J Cardiovasc Imaging*. 2022;38:683–93. doi: 10.1007/s10554-021-02429-3
 - 28 Al-Badri A, Tahhan AS, Sabbak N, *et al.* Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease. *J Am Heart Assoc*. 2020;9:e015515. doi: 10.1161/JAHA.119.015515
 - 29 Johnson BD, Shaw LJ, Pepine CJ, *et al.* Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: Results from the NIH-NHLBI-sponsored women's ischaemia syndrome evaluation (WISE) study. *Eur Heart J*. 2006;27:1408–15. doi: 10.1093/eurheartj/ehl040
 - 30 Douglas PS, Hoffmann U, Patel MR, *et al.* Outcomes of anatomical versus functional testing for coronary artery disease. *N Engl J Med*. 2015;372:1291–300. doi: 10.1056/NEJMoa1415516
 - 31 Maddox TM, Stanislawski MA, Grunwald GK, *et al.* Nonobstructive coronary artery disease and risk of myocardial infarction. *JAMA*. 2014;312:1754–63. doi: 10.1001/jama.2014.14681
 - 32 Bugiardini R, Bairey Merz CN. Angina with “normal” coronary arteries: a changing philosophy. *JAMA*. 2005;293:477–84. doi: 10.1001/jama.293.4.477
 - 33 Lichtlen PR, Bargheer K, Wenzlaff P. Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. *J Am Coll Cardiol*. 1995;25:1013–8. doi: 10.1016/0735-1097(94)00519-v
 - 34 Kaski JC, Rosano GM, Collins P, *et al.* Cardiac syndrome X: clinical characteristics and left

1
2
3 506 ventricular function. Long-term follow-up study. *J Am Coll Cardiol*. 1995;25:807–14. doi:
4 507 10.1016/0735-1097(94)00507-M
5
6
7 508 35 Sharaf BL, Pepine CJ, Kerensky RA, *et al*. Detailed angiographic analysis of women with
8 509 suspected ischemic chest pain (pilot phase data from the NHLBI-sponsored Women’s Ischemia
9 510 Syndrome Evaluation [WISE] Study Angiographic Core Laboratory). *Am J Cardiol*. 2001;87:937–
10 511 41; A3. doi: 10.1016/s0002-9149(01)01424-2
11
12
13 512 36 Kenkre TS, Malhotra P, Johnson BD, *et al*. Ten-Year Mortality in the WISE Study (Women’s
14 513 Ischemia Syndrome Evaluation). *Circ Cardiovasc Qual Outcomes*. 2017;10:e003863. doi:
15 514 10.1161/CIRCOUTCOMES.116.003863
16
17
18 515 37 Sedlak TL, Lee M, Izadnegahdar M, *et al*. Sex differences in clinical outcomes in patients with
19 516 stable angina and no obstructive coronary artery disease. *Am Heart J*. 2013;166:38–44. doi:
20 517 10.1016/j.ahj.2013.03.015
21
22
23 518 38 Smilowitz NR, Prasad M, Widmer RJ, *et al*. Comprehensive Management of ANOCA, Part 2-
24 519 Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art Review. *J Am*
25 520 *Coll Cardiol*. 2023;82:1264–79. doi: 10.1016/j.jacc.2023.06.044
26
27
28 521 39 Sedlak T, Herscovici R, Cook-Wiens G, *et al*. Predicted Versus Observed Major Adverse Cardiac
29 522 Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease:
30 523 A Report From WISE (Women’s Ischemia Syndrome Evaluation). *J Am Heart Assoc*.
31 524 2020;9:e013234. doi: 10.1161/JAHA.119.013234
32
33
34 525 40 Moreau P, d’Uscio LV, Lüscher TF. Structure and reactivity of small arteries in aging. *Cardiovasc*
35 526 *Res*. 1998;37:247–53. doi: 10.1016/s0008-6363(97)00225-3
36
37
38 527 41 Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and
39 528 treatment. *Coron Artery Dis*. 2018;29:161–7. doi: 10.1097/MCA.0000000000000598
40
41
42 529 42 Gan T, Hu J, Liu W, *et al*. Causal Association Between Anemia and Cardiovascular Disease: A 2-
43 530 Sample Bidirectional Mendelian Randomization Study. *J Am Heart Assoc*. 2023;12:e029689. doi:
44 531 10.1161/JAHA.123.029689
45
46
47 532 43 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated
48 533 with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure.
49 534 *Circulation*. 2003;107:223–5. doi: 10.1161/01.cir.0000052622.51963.fc
50
51
52 535 44 Herzog CA, Asinger RW, Berger AK, *et al*. Cardiovascular disease in chronic kidney disease. A
53 536 clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int*.
54 537 2011;80:572–86. doi: 10.1038/ki.2011.223
55
56
57 538 45 Liu F, Ma G, Tong C, *et al*. Elevated blood urea nitrogen-to-creatinine ratio increased the risk of
58 539 Coronary Artery Disease in patients living with type 2 diabetes mellitus. *BMC Endocr Disord*.
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Superior (ABES)

- 2022;22:50. doi: 10.1186/s12902-022-00954-3
- 46 Kirtane AJ, Leder DM, Waikar SS, *et al.* Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. *J Am Coll Cardiol.* 2005;45:1781–6. doi: 10.1016/j.jacc.2005.02.068
 - 47 He X, Liu C, Chen Y, *et al.* Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. *Can J Cardiol.* 2018;34:999–1003. doi: 10.1016/j.cjca.2018.03.013
 - 48 Wannamethee SG, Shaper AG, Lennon L, *et al.* Mild hyponatremia, hypernatremia and incident cardiovascular disease and mortality in older men: A population-based cohort study. *Nutr Metab Cardiovasc Dis NMCD.* 2016;26:12–9. doi: 10.1016/j.numecd.2015.07.008
 - 49 Ahn SY, Park YS, Lee SW, *et al.* Association Between Small Decrease in Serum Sodium Concentration within the Normal Range and All-Cause and Cardiovascular Mortality in Elderly Adults over 5 Years. *J Am Geriatr Soc.* 2016;64:510–7. doi: 10.1111/jgs.13937
 - 50 Sajadieh A, Binici Z, Mouridsen MR, *et al.* Mild hyponatremia carries a poor prognosis in community subjects. *Am J Med.* 2009;122:679–86. doi: 10.1016/j.amjmed.2008.11.033
 - 51 Doust JA, Pietrzak E, Dobson A, *et al.* How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. *BMJ.* 2005;330:625. doi: 10.1136/bmj.330.7492.625
 - 52 McKie PM, Rodeheffer RJ, Cataliotti A, *et al.* Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. *Hypertens Dallas Tex* 1979. 2006;47:874–80. doi: 10.1161/01.HYP.0000216794.24161.8c
 - 53 Wang TJ, Larson MG, Levy D, *et al.* Plasma natriuretic peptide levels and the risk of cardiovascular events and death. *N Engl J Med.* 2004;350:655–63. doi: 10.1056/NEJMoa031994
 - 54 Rosenberg J, Schou M, Gustafsson F, *et al.* Prognostic threshold levels of NT-proBNP testing in primary care. *Eur Heart J.* 2009;30:66–73. doi: 10.1093/eurheartj/ehn525
 - 55 Kistorp C, Raymond I, Pedersen F, *et al.* N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. *JAMA.* 2005;293:1609–16. doi: 10.1001/jama.293.13.1609
 - 56 Thomas L, Abhayaratna WP. Left Atrial Reverse Remodeling: Mechanisms, Evaluation, and Clinical Significance. *JACC Cardiovasc Imaging.* 2017;10:65–77. doi: 10.1016/j.jcmg.2016.11.003
 - 57 Krahn AD, Manfreda J, Tate RB, *et al.* The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med.* 1995;98:476–84. doi:

1
2
3 574 10.1016/S0002-9343(99)80348-9
4
5
6 575 58 Marsan NA, Maffessanti F, Tamborini G, *et al.* Left atrial reverse remodeling and functional
7 576 improvement after mitral valve repair in degenerative mitral regurgitation: a real-time 3-
8 577 dimensional echocardiography study. *Am Heart J.* 2011;161:314–21. doi:
9 578 10.1016/j.ahj.2010.10.029
10
11
12 579 59 Lloyd-Jones DM, Wang TJ, Leip EP, *et al.* Lifetime risk for development of atrial fibrillation: the
13 580 Framingham Heart Study. *Circulation.* 2004;110:1042–6. doi:
14 581 10.1161/01.CIR.0000140263.20897.42
15
16
17 582 60 Bozkurt B, Coats AJS, Tsutsui H, *et al.* Universal definition and classification of heart failure: a
18 583 report of the Heart Failure Society of America, Heart Failure Association of the European Society
19 584 of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition
20 585 of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of
21 586 India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. *Eur*
22 587 *J Heart Fail.* 2021;23:352–80. doi: 10.1002/ejhf.2115
23
24
25
26 588 61 Heidenreich PA, Bozkurt B, Aguilar D, *et al.* 2022 AHA/ACC/HFSA Guideline for the
27 589 Management of Heart Failure: A Report of the American College of Cardiology/American Heart
28 590 Association Joint Committee on Clinical Practice Guidelines. *Circulation.* 2022;145:e895–1032.
29 591 doi: 10.1161/CIR.0000000000001063
30
31
32
33
34
35

36 593 **Figure and table**

37
38
39 594 **Figure 1. Flowchart of study participation.** CAD, coronary artery disease.
40
41

42 595
43
44
45 596 **Figure 2. Variable Selection Based on LASSO Regression.** (A) Variation Characteristics of Variable
46
47
48 597 Coefficients; (B) Selection Process of Optimal λ Value in LASSO Regression Model Using Cross-
49
50 598 Validation.
51
52

53 599
54
55
56 600 **Figure 3. Nomogram for predicting the probability of 1-, 2-, and 3-year event-free survival of**
57
58 601 **ANOCA patients as assessed by coronary angiography.** ALT, alanine transaminase; AST, aspartate
59
60

transaminase; LVEF, left ventricular ejection fraction.

Figure 4. Receiver operating characteristic curve for the 1-, 2-, and 3-year primary endpoints of the nomogram in the training set (A) and validation set (B). AUC, area under the curve.

Figure 5. Calibration plot of predicted 1-, 2-, and 3-year event-free survival based on the nomogram in the training set and validation set. (A–C) Training set; (D–F) Validation set.

Figure 6. Decision curve analysis of the nomogram in the training cohort (A) and validation cohort (B). The x-axis represents the threshold probability, and the y-axis measures the net benefit. The left-slanting straight line shows the net benefit of treating all patients. The bottom horizontal gray line represents the net benefit of not treating any patients. The curve in the middle represents the nomogram.

Figure 7. Kaplan-Meier curves for primary endpoint event-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

Supplementary Table 1. Clinical data of the total population, training set and validation set.

Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population.

1
2
3
4 623
5
6
7 624
8
9
10 625
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Consecutive patients underwent coronary angiography
(n =17816)

Patients excluded:

Obstructive CAD (n =9883)

Prior CAD (n =1816)

Missing baseline or follow-up data (n =131)

Severe diseases (n = 52)

Accessed for enrolled (n =5934)

Randomly assigned (0.75:0.25)

Train set (n=4452)

Validation set (n=1482)

LASSO and COX regression


Internal validation

Nomogram


Discrimination and
calibration


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A




B












1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A





B






Downloaded from <http://bmjopen.bmj.com/> on June 8, 2025 at Agence Bibliographique de l'Enseignement Supérieur (ABES).
All rights reserved. No reuse allowed without permission.
by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Number at risk

Low	3946	2875	1906	927	66
High	506	353	189	71	10

Time (Days)



Number at risk

Low	1336	993	648	325	34
High	146	92	51	20	0

Time (Days)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplement

For peer review only

Enseignement Supérieur (ABES) .
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.


Supplementary Table 1. Clinical data of the total population, training set and validation set.

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
Female, n (%)	3462 (58.3%)	2609 (58.6%)	853 (57.6%)	0.499
Age, years	43.6 (10.8)	43.7 (10.9)	43.5 (10.6)	0.563
Smoking, n (%)	1509 (25.4%)	1126 (25.3%)	383 (25.8%)	0.698
Drinking, n (%)	1883 (31.7%)	1415 (31.8%)	468 (31.6%)	0.909
Hypertension, n (%)	3698 (62.3%)	2802 (62.9%)	896 (60.5%)	0.094
Diabetes mellitus, n (%)	1123 (18.9%)	846 (19.0%)	277 (18.7%)	0.820
Diabetic complications, n (%)	19 (0.32%)	13 (0.29%)	6 (0.40%)	0.595
Dyslipidemia, n (%)	582 (9.81%)	423 (9.50%)	159 (10.7%)	0.185
CKD, n (%)	202 (3.40%)	151 (3.39%)	51 (3.44%)	0.993
SBP, mmHg	136 (19.8)	136 (19.9)	136 (19.7)	0.340
DBP, mmHg	81.9 (12.3)	81.9 (12.4)	81.8 (11.9)	0.757
Heart rate, beats/min	73.8 (15.2)	73.8 (13.9)	73.9 (18.5)	0.798
WBC, 10 ⁹ /L	6.67 (2.03)	6.68 (2.01)	6.67 (2.11)	0.969
Hemoglobin, g/L	136 (16.6)	136 (16.6)	136 (16.4)	0.881
Urea, mmol/L	6.09 (2.68)	6.09 (2.72)	6.08 (2.57)	0.831
Serum creatinine, µmol/L	65.9 [55.7; 79.8]	66.2 [55.7; 79.7]	65.4 [55.5; 80.0]	0.748
Uric acid, µmol/L	335 (100)	335 (101)	335 (99.0)	0.889
Serum sodium, mmol/L	142 (3.51)	142 (3.32)	142 (4.01)	0.829
Serum potassium, mmol/L	4.12 (0.56)	4.12 (0.47)	4.13 (0.76)	0.649
Serum chloride, mmol/L	106 (3.37)	106 (3.42)	106 (3.21)	0.515
Anion gap, mmol/L	14.0 (2.40)	13.9 (2.40)	14.0 (2.42)	0.844

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
Total protein, g/L	68.2 (6.41)	68.2 (6.37)	68.2 (6.54)	0.968
Albumin, g/L	42.4 (3.88)	42.4 (3.87)	42.3 (3.91)	0.406
Globulin, g/L	25.9 (4.19)	25.8 (4.16)	25.9 (4.30)	0.353
ALT, U/L	17.7 [13.0; 24.7]	17.8 [13.1; 24.8]	17.6 [12.6; 24.5]	0.169
AST, U/L	17.7 [14.6; 21.6]	17.8 [14.6; 21.6]	17.5 [14.6; 21.5]	0.341
ALT/AST ratio	1.06 (0.41)	1.05 (0.41)	1.07 (0.42)	0.157
Total bilirubin, µmol/L	13.6 (6.67)	13.6 (6.81)	13.4 (6.23)	0.257
Indirect Bilirubin, µmol/L	9.63 (4.69)	9.67 (4.75)	9.51 (4.53)	0.242
Direct Bilirubin, µmol/L	3.40 [2.30; 4.60]	3.40 [2.30; 4.60]	3.40 [2.40; 4.60]	0.611
Alkaline phosphatase, U/L	76.5 (23.6)	76.5 (23.6)	76.6 (23.7)	0.820
Total cholesterol, mmol/L	4.75 (1.12)	4.75 (1.13)	4.74 (1.08)	0.919
Triglycerides, mmol/L	1.63 (1.11)	1.62 (1.11)	1.65 (1.10)	0.485
HDL-C, mmol/L	1.22 (0.31)	1.22 (0.32)	1.20 (0.30)	0.083
LDL-C, mmol/L	2.97 (0.88)	2.97 (0.88)	2.98 (0.87)	0.498
VLDL-C, mmol/L	0.56 (0.37)	0.56 (0.39)	0.56 (0.30)	0.627
Troponin I, ng/ml	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.01 [0.01; 0.03]	0.536
NT-proBNP, ng/L	83.7 [35.1; 266]	83.0 [34.3; 265]	86.7 [38.0; 269]	0.415
CKMB, U/L	12.1 [9.30; 14.7]	12.0 [9.24; 14.7]	12.3 [9.30; 14.7]	0.529
D-Dimer, µg/L	276 [2.34; 434]	274 [1.78; 427]	282 [4.65; 457]	0.110
Glucose, mmol/L	6.81 (2.48)	6.82 (2.45)	6.78 (2.56)	0.579
Left atrial diameter, mm	38.7 (5.24)	38.7 (5.28)	38.6 (5.11)	0.331

Variable	Total	Train set	Validation set	p value
	N=5934	N=4452	N=1482	
LVEDD, mm	47.4 (4.46)	47.4 (4.51)	47.3 (4.28)	0.373
LVESD, mm	26.9 (5.62)	26.9 (5.65)	27.0 (5.52)	0.737
RVEDD, mm	20.8 (3.37)	20.7 (3.61)	20.8 (2.53)	0.623
LVEF, %	61.7 (6.75)	61.7 (6.77)	61.6 (6.70)	0.486
Event-free survival time, days	635 (403)	633 (402)	641 (406)	0.512
Death, n (%)	106 (1.79%)	78 (1.75%)	28 (1.89%)	0.816
MI endpoint, n (%)	33 (0.56%)	21 (0.47%)	12 (0.81%)	0.189
Stroke endpoint, n (%)	11 (0.19%)	6 (0.13%)	5 (0.34%)	0.156
MACE, n (%)	82 (1.38%)	64 (1.44%)	18 (1.21%)	0.611
Primary endpoint, n (%)	145 (2.44%)	105 (2.36%)	40 (2.70%)	0.523


CKD, chronic kidney disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, white blood cell; ALT, alanine transaminase; AST, aspartate transaminase; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-B-type natriuretic peptide; CKMB, creatine kinase-MB; LVEDD, left ventricular-end-diastolic diameter; LVESD, left ventricular-end-systolic diameter; RVEDD, right ventricular-end-diastolic diameter; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MACE, major adverse cardiovascular events.




Supplementary Figure 1. Event-free survival probability of different adverse outcomes in the total population

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

A



B



Supplementary Figure 2. Kaplan-Meier curves for MACE-free survival in the low-risk and high-risk groups in the training set (A) and validation set (B).